US20220193194A9 - Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent - Google Patents
Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent Download PDFInfo
- Publication number
- US20220193194A9 US20220193194A9 US16/712,816 US201916712816A US2022193194A9 US 20220193194 A9 US20220193194 A9 US 20220193194A9 US 201916712816 A US201916712816 A US 201916712816A US 2022193194 A9 US2022193194 A9 US 2022193194A9
- Authority
- US
- United States
- Prior art keywords
- ici
- treatment
- factors
- cancer
- cancer patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 186
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title claims abstract description 181
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title claims abstract description 181
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title claims abstract description 180
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title claims abstract description 180
- 201000011510 cancer Diseases 0.000 title claims abstract description 121
- 238000000034 method Methods 0.000 title claims abstract description 44
- 239000003814 drug Substances 0.000 title description 13
- 229940124597 therapeutic agent Drugs 0.000 title description 3
- 238000011282 treatment Methods 0.000 claims abstract description 194
- 230000004044 response Effects 0.000 claims abstract description 93
- 230000002349 favourable effect Effects 0.000 claims abstract description 33
- 230000000694 effects Effects 0.000 claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 210000004369 blood Anatomy 0.000 claims description 49
- 239000008280 blood Substances 0.000 claims description 49
- 102000004889 Interleukin-6 Human genes 0.000 claims description 44
- 108090001005 Interleukin-6 Proteins 0.000 claims description 44
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 40
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 33
- 210000002381 plasma Anatomy 0.000 claims description 33
- 238000011275 oncology therapy Methods 0.000 claims description 29
- 230000008859 change Effects 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 230000000381 tumorigenic effect Effects 0.000 claims description 25
- 231100000588 tumorigenic Toxicity 0.000 claims description 24
- 102000007299 Amphiregulin Human genes 0.000 claims description 23
- 108010033760 Amphiregulin Proteins 0.000 claims description 23
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 23
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 20
- 239000003102 growth factor Substances 0.000 claims description 20
- 102000004127 Cytokines Human genes 0.000 claims description 18
- 108090000695 Cytokines Proteins 0.000 claims description 18
- LSONWRHLFZYHIN-UHFFFAOYSA-N 2-[(4-phenoxyphenyl)sulfonylmethyl]thiirane Chemical group C=1C=C(OC=2C=CC=CC=2)C=CC=1S(=O)(=O)CC1CS1 LSONWRHLFZYHIN-UHFFFAOYSA-N 0.000 claims description 17
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 17
- 230000001480 pro-metastatic effect Effects 0.000 claims description 16
- 102000005962 receptors Human genes 0.000 claims description 16
- 108020003175 receptors Proteins 0.000 claims description 16
- 230000000770 proinflammatory effect Effects 0.000 claims description 15
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 14
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 13
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 12
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 12
- 230000001023 pro-angiogenic effect Effects 0.000 claims description 12
- -1 ICOS Proteins 0.000 claims description 11
- 229960005386 ipilimumab Drugs 0.000 claims description 11
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 11
- 230000002062 proliferating effect Effects 0.000 claims description 11
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 11
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 102000000588 Interleukin-2 Human genes 0.000 claims description 10
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 9
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102100037850 Interferon gamma Human genes 0.000 claims description 9
- 108010074328 Interferon-gamma Proteins 0.000 claims description 9
- 102000017761 Interleukin-33 Human genes 0.000 claims description 9
- 108010067003 Interleukin-33 Proteins 0.000 claims description 9
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 claims description 8
- 102000003814 Interleukin-10 Human genes 0.000 claims description 8
- 108090000174 Interleukin-10 Proteins 0.000 claims description 8
- 108010002586 Interleukin-7 Proteins 0.000 claims description 8
- 229960003301 nivolumab Drugs 0.000 claims description 8
- 229960002621 pembrolizumab Drugs 0.000 claims description 8
- 108091005660 ADAMTS1 Proteins 0.000 claims description 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 7
- 102100036849 C-C motif chemokine 24 Human genes 0.000 claims description 7
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 7
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 7
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 7
- 102000003816 Interleukin-13 Human genes 0.000 claims description 7
- 108090000176 Interleukin-13 Proteins 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims description 7
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 7
- 239000005482 chemotactic factor Substances 0.000 claims description 7
- 230000037361 pathway Effects 0.000 claims description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 108010081589 Becaplermin Proteins 0.000 claims description 6
- 108010083647 Chemokine CCL24 Proteins 0.000 claims description 6
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 6
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 6
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 claims description 6
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 claims description 6
- 102000019034 Chemokines Human genes 0.000 claims description 5
- 108010012236 Chemokines Proteins 0.000 claims description 5
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 5
- 101000978374 Mus musculus C-C motif chemokine 12 Proteins 0.000 claims description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 5
- 230000003399 chemotactic effect Effects 0.000 claims description 5
- 229950009791 durvalumab Drugs 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 229950007217 tremelimumab Drugs 0.000 claims description 5
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 101150022345 GAS6 gene Proteins 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 229960003852 atezolizumab Drugs 0.000 claims description 4
- 229950002916 avelumab Drugs 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 101150021185 FGF gene Proteins 0.000 claims description 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 3
- 108010043610 KIR Receptors Proteins 0.000 claims description 3
- 102000002698 KIR Receptors Human genes 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 3
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 3
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 claims description 3
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 claims description 3
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 229950010773 pidilizumab Drugs 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 229950007213 spartalizumab Drugs 0.000 claims description 3
- 210000001541 thymus gland Anatomy 0.000 claims description 3
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 229940125566 REGN3767 Drugs 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 230000001270 agonistic effect Effects 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 229940121569 ieramilimab Drugs 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 229950011263 lirilumab Drugs 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229940121484 relatlimab Drugs 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000002381 testicular Effects 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000009377 thymus cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 208000037964 urogenital cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 5
- 229960000106 biosimilars Drugs 0.000 claims 4
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 3
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 3
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 3
- 102100027398 A disintegrin and metalloproteinase with thrombospondin motifs 1 Human genes 0.000 claims 2
- 102100023698 C-C motif chemokine 17 Human genes 0.000 claims 2
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 2
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 claims 2
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 2
- 102000000704 Interleukin-7 Human genes 0.000 claims 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229940121420 cemiplimab Drugs 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 1
- 101710177504 Kit ligand Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 101100514842 Xenopus laevis mtus1 gene Proteins 0.000 claims 1
- 229950001565 clazakizumab Drugs 0.000 claims 1
- 238000011443 conventional therapy Methods 0.000 claims 1
- 229950002507 elsilimomab Drugs 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 229940059237 olamkicept Drugs 0.000 claims 1
- 229950010006 olokizumab Drugs 0.000 claims 1
- 229940121310 onvatilimab Drugs 0.000 claims 1
- 229950006348 sarilumab Drugs 0.000 claims 1
- 229960003323 siltuximab Drugs 0.000 claims 1
- 229950006094 sirukumab Drugs 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 229950007269 vobarilizumab Drugs 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 93
- 229940100601 interleukin-6 Drugs 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 34
- 238000002560 therapeutic procedure Methods 0.000 description 29
- 230000004083 survival effect Effects 0.000 description 28
- 230000004614 tumor growth Effects 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 238000011725 BALB/c mouse Methods 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 13
- 230000031018 biological processes and functions Effects 0.000 description 13
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 230000000903 blocking effect Effects 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 238000002648 combination therapy Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 210000002865 immune cell Anatomy 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 9
- 101800003838 Epidermal growth factor Proteins 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000033115 angiogenesis Effects 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 229940116977 epidermal growth factor Drugs 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 230000004043 responsiveness Effects 0.000 description 8
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 8
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 7
- 208000006265 Renal cell carcinoma Diseases 0.000 description 7
- 201000008275 breast carcinoma Diseases 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000009097 single-agent therapy Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 102000001301 EGF receptor Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 6
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 6
- 102100026019 Interleukin-6 Human genes 0.000 description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 6
- 238000011579 SCID mouse model Methods 0.000 description 6
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 5
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 5
- 102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 description 5
- 101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 description 5
- 101710178302 Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
- 108010014612 Follistatin Proteins 0.000 description 4
- 102000016970 Follistatin Human genes 0.000 description 4
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 4
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 4
- 102000013691 Interleukin-17 Human genes 0.000 description 4
- 108050003558 Interleukin-17 Proteins 0.000 description 4
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 4
- 102100035194 Placenta growth factor Human genes 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000035605 chemotaxis Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- 102100023701 C-C motif chemokine 18 Human genes 0.000 description 3
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 3
- 102100039396 C-X-C motif chemokine 16 Human genes 0.000 description 3
- 108090000613 Cathepsin S Proteins 0.000 description 3
- 102100035654 Cathepsin S Human genes 0.000 description 3
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102000044465 Galectin-7 Human genes 0.000 description 3
- 101000608772 Homo sapiens Galectin-7 Proteins 0.000 description 3
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 description 3
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 3
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 3
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 3
- 102000003810 Interleukin-18 Human genes 0.000 description 3
- 108090000171 Interleukin-18 Proteins 0.000 description 3
- 102100026236 Interleukin-8 Human genes 0.000 description 3
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 3
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 3
- 102100030304 Platelet factor 4 Human genes 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 190000008236 carboplatin Chemical compound 0.000 description 3
- 238000012754 cardiac puncture Methods 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229950006370 epacadostat Drugs 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000003498 protein array Methods 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 2
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 2
- 102100022987 Angiogenin Human genes 0.000 description 2
- 102000009088 Angiopoietin-1 Human genes 0.000 description 2
- 108010048154 Angiopoietin-1 Proteins 0.000 description 2
- 102100034608 Angiopoietin-2 Human genes 0.000 description 2
- 108010048036 Angiopoietin-2 Proteins 0.000 description 2
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 2
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 2
- 102100025250 C-X-C motif chemokine 14 Human genes 0.000 description 2
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 2
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 2
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 2
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000858068 Homo sapiens C-X-C motif chemokine 14 Proteins 0.000 description 2
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 2
- 101001076422 Homo sapiens Interleukin-1 receptor type 2 Proteins 0.000 description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000606535 Homo sapiens Receptor-type tyrosine-protein phosphatase epsilon Proteins 0.000 description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 2
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 2
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 2
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 2
- 102100026017 Interleukin-1 receptor type 2 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102400000401 Latency-associated peptide Human genes 0.000 description 2
- 101800001155 Latency-associated peptide Proteins 0.000 description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 2
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 description 2
- 101710130688 Neuronal cell adhesion molecule Proteins 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 102100029268 Neurotrophin-3 Human genes 0.000 description 2
- 108090000630 Oncostatin M Proteins 0.000 description 2
- 102100031942 Oncostatin-M Human genes 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 102100039665 Receptor-type tyrosine-protein phosphatase epsilon Human genes 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108010066451 Triggering Receptor Expressed on Myeloid Cells-1 Proteins 0.000 description 2
- 102100029681 Triggering receptor expressed on myeloid cells 1 Human genes 0.000 description 2
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 2
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 108010072788 angiogenin Proteins 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000008236 biological pathway Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000007248 cellular mechanism Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 2
- 229960002204 daratumumab Drugs 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229940029303 fibroblast growth factor-1 Drugs 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 229940126546 immune checkpoint molecule Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 244000309459 oncolytic virus Species 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000007114 proinflammatory cascade Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940034785 sutent Drugs 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- RWRDJVNMSZYMDV-SIUYXFDKSA-L (223)RaCl2 Chemical compound Cl[223Ra]Cl RWRDJVNMSZYMDV-SIUYXFDKSA-L 0.000 description 1
- BNIFSVVAHBLNTN-XKKUQSFHSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-4-amino-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexan Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O)CCC1 BNIFSVVAHBLNTN-XKKUQSFHSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- 102100035990 Adenosine receptor A2a Human genes 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 229940125431 BRAF inhibitor Drugs 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102100036841 C-C motif chemokine 1 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 1
- 102100023700 C-C motif chemokine 16 Human genes 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 102100022287 C-Jun-amino-terminal kinase-interacting protein 2 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 101710098309 C-X-C motif chemokine 13 Proteins 0.000 description 1
- 101710098303 C-X-C motif chemokine 16 Proteins 0.000 description 1
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 description 1
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 101150011672 CCL9 gene Proteins 0.000 description 1
- 102100027209 CD2-associated protein Human genes 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108010082548 Chemokine CCL11 Proteins 0.000 description 1
- 108010082155 Chemokine CCL18 Proteins 0.000 description 1
- 108010082161 Chemokine CCL19 Proteins 0.000 description 1
- 102000003805 Chemokine CCL19 Human genes 0.000 description 1
- 108010083702 Chemokine CCL21 Proteins 0.000 description 1
- 108010083698 Chemokine CCL26 Proteins 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
- 102100024539 Chymase Human genes 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 101100107081 Danio rerio zbtb16a gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100035989 E3 SUMO-protein ligase PIAS1 Human genes 0.000 description 1
- 102100031918 E3 ubiquitin-protein ligase NEDD4 Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000872838 Hepatitis B virus genotype C subtype adr (isolate China/NC-1/1988) Small envelope protein Proteins 0.000 description 1
- 102100032509 Histamine H1 receptor Human genes 0.000 description 1
- 101000864666 Homo sapiens ATP-dependent RNA helicase DHX8 Proteins 0.000 description 1
- 101000783751 Homo sapiens Adenosine receptor A2a Proteins 0.000 description 1
- 101000799972 Homo sapiens Alpha-2-macroglobulin Proteins 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 description 1
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 1
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 description 1
- 101000978371 Homo sapiens C-C motif chemokine 18 Proteins 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 1
- 101001046656 Homo sapiens C-Jun-amino-terminal kinase-interacting protein 2 Proteins 0.000 description 1
- 101000916059 Homo sapiens C-X-C chemokine receptor type 2 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000889133 Homo sapiens C-X-C motif chemokine 16 Proteins 0.000 description 1
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 description 1
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000914499 Homo sapiens CD2-associated protein Proteins 0.000 description 1
- 101000715398 Homo sapiens Caspase-1 Proteins 0.000 description 1
- 101000909983 Homo sapiens Chymase Proteins 0.000 description 1
- 101000636713 Homo sapiens E3 ubiquitin-protein ligase NEDD4 Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001016841 Homo sapiens Histamine H1 receptor Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 description 1
- 101000966742 Homo sapiens Leucine-rich PPR motif-containing protein, mitochondrial Proteins 0.000 description 1
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 description 1
- 101001076431 Homo sapiens NF-kappa-B inhibitor zeta Proteins 0.000 description 1
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
- 101000825404 Homo sapiens SH2 domain-containing adapter protein B Proteins 0.000 description 1
- 101000650806 Homo sapiens Semaphorin-3F Proteins 0.000 description 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 1
- 101100377226 Homo sapiens ZBTB16 gene Proteins 0.000 description 1
- 101000743802 Homo sapiens Zinc finger protein 675 Proteins 0.000 description 1
- 102000039996 IL-1 family Human genes 0.000 description 1
- 108091069196 IL-1 family Proteins 0.000 description 1
- 108010050332 IQ motif containing GTPase activating protein 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 1
- 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 description 1
- 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 102100033105 Interleukin-17C Human genes 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100040589 Leucine-rich PPR motif-containing protein, mitochondrial Human genes 0.000 description 1
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 101000946797 Mus musculus C-C motif chemokine 9 Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100026009 NF-kappa-B inhibitor zeta Human genes 0.000 description 1
- 238000011789 NOD SCID mouse Methods 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- 108090000770 Neuropilin-2 Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101150062285 PGF gene Proteins 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 108700003766 Promyelocytic Leukemia Zinc Finger Proteins 0.000 description 1
- 108010038241 Protein Inhibitors of Activated STAT Proteins 0.000 description 1
- 102100023068 Protein kinase C-binding protein NELL1 Human genes 0.000 description 1
- 102100034433 Protein kinase C-binding protein NELL2 Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100034419 Ras GTPase-activating-like protein IQGAP1 Human genes 0.000 description 1
- 102100024735 Resistin Human genes 0.000 description 1
- 108010047909 Resistin Proteins 0.000 description 1
- 102100022342 SH2 domain-containing adapter protein B Human genes 0.000 description 1
- 102100027751 Semaphorin-3F Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000005591 Swarts synthesis reaction Methods 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100040314 Zinc finger and BTB domain-containing protein 16 Human genes 0.000 description 1
- 102100039039 Zinc finger protein 675 Human genes 0.000 description 1
- 101710151579 Zinc metalloproteinase Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- 229940094732 darzalex Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 108091007231 endothelial receptors Proteins 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 108040001304 interleukin-17 receptor activity proteins Proteins 0.000 description 1
- 102000053460 interleukin-17 receptor activity proteins Human genes 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000011234 negative regulation of signal transduction Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- 108010012038 peptide 78 Proteins 0.000 description 1
- 229940125863 peptide 78 Drugs 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
- 230000016833 positive regulation of signal transduction Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 229940092814 radium (223ra) dichloride Drugs 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940081616 tafinlar Drugs 0.000 description 1
- 229950008461 talimogene laherparepvec Drugs 0.000 description 1
- 229940126625 tavolimab Drugs 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229950005972 urelumab Drugs 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 229950003520 utomilumab Drugs 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229940069559 votrient Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/20—Protein or domain folding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention is in the field of oncology and particularly relates to a method of treatment of a cancer patient with an immune checkpoint inhibitor in combination with another therapeutic agent.
- Host-mediated responses to anti-cancer treatment modalities may be molecular and/or cellular responses.
- BMDCs host bone marrow derived cells
- cancer therapy also induces pro-tumorigenic activation of various immune cells such as macrophages and antigen presenting cells (Beyar-Katz et al., 2016; De Palma and Lewis, 2013; Kim et al. 2012; Ma et al., 2013).
- ICIs immune checkpoint inhibitors
- Such immune-modulating drugs have shown remarkable successes for the treatment of advanced malignancies (including stage IV) such as melanoma, prostate, non-small cell lung cancer, renal cell carcinoma and also some hematological malignancies (Postow et al., 2015).
- stage IV advanced malignancies
- the human immune system is capable of recognizing and mounting a response to cancerous cells, this response is often circumvented by tumor-derived inhibition resulting in immune tolerance.
- tumor-infiltrating lymphocytes such as tumor antigen-specific CD8 + cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells
- CTLs cytotoxic T lymphocytes
- NK natural killer cells
- IL-10 is frequently upregulated in various types of cancer, and was shown to suppress the immune system (Sato et al., 2011).
- identifying molecules that negatively regulate the immune system against tumor cells will lead to the development of immunomodulatory drugs that support the activation of immune cells against tumors.
- immune checkpoint proteins such as CTLA-4, PD-1 and its ligand, PD-L1.
- These checkpoint proteins are expressed by tumor cells or other immune cells and contribute to the exhaustion of CTLs (Postow et al., 2015; Topalian et al., 2015). Specifically, they keep immune responses in check, and inhibit T cell killing effects against tumor cells.
- checkpoint inhibitors have been developed in order to inhibit the immune suppression effects.
- antibodies blocking the immune checkpoints CTLA-4 and PD-1 or its ligand PD-L1 have been developed (Pardoll, 2012). These ICIs are currently in use in the clinic for the treatment of various malignancies with some promising and remarkable successes (Romano and Romero, 2015).
- ICIs have shown therapeutic benefit only for a limited portion of cancer patients ( ⁇ 10-20%).
- pooled data from clinical studies of ipilimumab, a CTLA-4 blocking antibody revealed that the duration of clinical response is around 3 years, and can last up to 10 years.
- this dramatic therapeutic effect is only observed in a subset of patients ( ⁇ 20%).
- the majority of patients exhibit intrinsic resistance mechanisms to such therapies.
- the molecular aspects that define the subpopulation of patients that are responsive to ICIs are not fully clear. It has been suggested that markers such as PD-L1 expression by tumor cells, mutational burden, and lymphocytic infiltrates could predict the cancer patients that will respond to ICI immunotherapy.
- these aforementioned biomarkers do not always correlate with tumor responsiveness to ICI immunotherapy or resistance of patients to ICIs. Therefore, additional possible mechanisms are still unknown.
- the present invention is based on previous studies mentioned hereinbefore in the Background section of the application that show that a cancer patient (the “host”), in response to a cancer therapy, may generate and induce into the host circulation a set of host-driven resistance factors to cancer immunotherapy with an immune checkpoint inhibitor (hereinafter “ICI”), that may limit or counteract the effectiveness of the patient treatment with the ICI.
- ICI immune checkpoint inhibitor
- the determination of these factors allows the prediction in a personalized form of the favorable or non-favorable response of the patient to the treatment with the ICI.
- factors are factors, mainly cytokines, chemokines, growth factors, soluble receptors, enzymes and other molecules produced by the host cells, either at different organs or at the tumor microenvironment, in response to the cancer therapy with the ICI with which the patient is treated.
- the present invention provides a method of treating a cancer patient with an immune checkpoint inhibitor (ICI), the method comprising the steps of:
- step (ii) obtaining reference levels for each of the one or more of the plurality of the host-driven resistance factors of step (i) by determining the levels of each of said factors in a blood sample of the same type of the blood sample of step (i), obtained from the cancer patient at a time point before said session of treatment with the ICI;
- step (iii) establishing the fold change for each of the one or more of the plurality of the host-driven resistance factors of step (i) by comparing the level of each host-driven resistance factor of step (i) with the reference level of step (ii) for the same factor;
- step (iv) determining that the cancer patient has a favorable or a non-favorable response to the treatment with said ICI based on the fold change established in step (iii) for one or more of the plurality of host-driven resistance factors of step (i);
- step (iva) if the cancer patient has a non-favorable response to the treatment with said ICI based on the fold change established in step (iii) for one or more of the plurality of the host-driven resistance factors, then selecting a dominant factor among the one or more host-driven resistance factors showing a fold change indicative of said non-favorable response, and treating the patient with a therapeutically effective amount of the ICI along with a therapeutically effective amount of an agent that blocks the activity of the selected dominant host-driven resistance factor (herein “the dominant factor”) or the receptor thereof; or
- the invention relates to a method for treatment of a cancer patient non-responsive to treatment with an immune checkpoint inhibitor (ICI), the method comprising administering to the cancer patient a therapeutically effective amount of the ICI in combination with a therapeutically effective amount of an agent that blocks the activity of a dominant factor, or of the receptor thereof, the dominant factor being selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, the plurality of host-driven resistance factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the ICI, wherein the fold change is established by comparing: (i) the level of each host-driven resistance factors in a blood sample selected from blood plasma, whole blood, blood serum or peripheral blood mononuclear cells, obtained from the cancer patient after a session of treatment with the ICI, with (ii) a reference level obtained for the same factor from a blood sample of the same type of (i), obtained from the cancer patient before said session of treatment with the ICI
- ICI immune
- the present invention relates to an immune checkpoint inhibitor (ICI), for use in the treatment of cancer in a patient non-responsive to said treatment, comprising administering a therapeutically effective amount of the ICI in combination with a therapeutically effective amount of an agent that blocks the activity of a dominant factor, or of the receptor thereof, the dominant factor being selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, the plurality of host-driven resistance factors having a fold-change predictive of a non-favorable response of the cancer epatient to the treatment with the ICI, wherein the fold change is established by comparing: (i) the level of each host-driven resistance factor in a blood sample selected from blood plasma, whole blood, blood serum or peripheral blood mononuclear cells, obtained from the cancer patient after a session of treatment with the ICI, with (ii) a reference level obtained for the same factor from a blood sample of the same type of (i), obtained from the cancer patient before said session of treatment with the ICI.
- ICI immune
- FIGS. 1A-1D show the effect of blocking MMP9 on primary tumor growth and survival in a mouse model of breast cancer.
- FIG. 1A shows that mice treated with a combination of anti-PD-L1 and the MMP-2/MMP-9 inhibitor SB-3CT exhibit reduced tumor size compared to mice treated with vehicle, anti-PD-L1 or SB-3CT alone.
- FIG. 1B shows tumor volume at day 27, the last experimental day.
- FIG. 1C shows better response rate and reduced tumor size for individual mice treated with the combined therapy compared to anti-PD-L1 alone.
- FIG. 1D shows better survival of mice treated with the combined therapy compared to the other treatment groups.
- FIGS. 2A-2C show the effect of blocking host-derived amphiregulin on primary tumor growth and survival in a mouse model of colon cancer.
- FIGS. 2A-2B show tumor volume of mice treated with anti-PD-L1, anti-amphiregulin antibody (anti-AREG) or anti-PD-L1 and anti-AREG combined therapy.
- FIG. 2C is a Kaplan-Meier curve demonstrating better survival of mice treated with the combined therapy compared to the other treatment groups.
- FIG. 3 shows IL-6 expression following treatment with anti-PD-L1 or anti-CTLA-4.
- FIGS. 4A-4C show the effect of blocking host-derived IL-6 induced following treatment with anti-PD-L1 on primary tumor growth and mice survival.
- FIG. 4A shows inhibition in tumor growth in mice treated with a combination of anti-PD-L1 and anti-IL-6 compared to control mice or mice treated with either anti-PD-L1 or anti-IL-6 alone.
- FIG. 4B corresponds to FIG. 4A , but shows tumor growth in individual animals, and
- FIG. 4C shows that combined treatment with both anti-PD-L1 and anti-IL-6 also led to better survival relative to the other treatment groups.
- FIGS. 5A-5B show the effect of blocking host-derived IL-6 induced following treatment with anti-CTLA-4 on primary tumor growth and survival.
- Treatment of BALB/c mice with anti-CTLA-4 resulted in reduced tumor growth ( FIG. 5A ) and better survival relative to control mice ( FIG. 5B ), and these effects were further improved by combined treatment with both anti-CTLA-4 and anti-IL-6 antibodies ( FIGS. 5A-5B ).
- a cancer therapy may be used interchangeably with the term “a “a cancer-modality therapy”, and include plural reference, namely, one single modality therapy or a combination of two or more modality therapies.
- induced As used herein, the terms “induced”, “driven” and “generated” are used interchangeably to denote the factors induced into the circulation by the cancer patient in response to the cancer therapy (“host-response”).
- a cycle of treatment means that the drug is administered to the patient at one point in time (for example, injections over a day or two) and then there is some time (e.g., 1, 2 or 3 weeks) with no treatment.
- a session of treatment refers to the “one point in time” when the ICI is administered to the patient at the beginning of a cycle of treatment.
- the treatment and rest time make up one “treatment cycle”.
- a series of cycles of treatment is called “a course”.
- an immune checkpoint inhibitor refers to a single ICI, a combination of ICIs and a combination of an ICI with another cancer therapy.
- the ICI may be a monoclonal antibody, a humanized antibody, a fully human antibody, a fusion protein or a combination thereof.
- the invention relates to a method of treating a cancer patient with an immune checkpoint inhibitor (ICI), the method comprising the steps of:
- step (ii) obtaining reference levels for each of the one or more of the plurality of the host-driven resistance factors of step (i) by determining the levels of each of said factors in a blood sample of the same type of the blood sample of step (i), obtained from the cancer patient at a time point before said session of treatment with the ICI;
- step (iii) establishing the fold change for each of the one or more of the plurality of the host-driven resistance factors of step (i) by comparing the level of each host-driven resistance factor of step (i) with the reference level of step (ii) for the same factor;
- step (iv) determining that the cancer patient has a favorable or a non-favorable response to the treatment with said ICI based on the fold change established in step (iii) for one or more of the plurality of host-driven resistance factors of step (i);
- step (iva) if the cancer patient has a non-favorable response to the treatment with said ICI based on the fold change established in step (iii) for one or more of the plurality of the host-driven resistance factors, then selecting a dominant factor among the one or more host-driven resistance factors showing a fold change indicative of said non-favorable response, and treating the patient with a therapeutically effective amount of the ICI along with a therapeutically effective amount of an agent that blocks the activity of the selected dominant host-driven resistance factor (herein “the dominant factor”), or of the receptor thereof; or
- a “favorable response” of the cancer patient indicates “responsiveness” of the cancer patient to the treatment with the ICI, namely, the treatment of the responsive cancer patient with the ICI will lead to the desired clinical outcome such as tumor regression, tumor shrinkage or tumor necrosis; an anti-tumor response by the immune system; preventing or delaying tumor recurrence tumor growth or tumor metastasis.
- the treatment of the responsive cancer patient with the ICI alone, as defined in step (ivb) above.
- a “non-favorable response” of the cancer patient indicates “non-responsiveness” of the cancer patient to the treatment with the ICI due to induction of host-driven resistance factors that may be pro-tumorigenic, e.g., pro-angiogenic, pro-inflammatory/chemotactic or proliferative growth factors, or pro-metastatic factors, and thus the treatment of the non-responsive cancer patient with the ICI will not lead to the desired clinical outcome but to non-desired outcomes such as tumor expansion, recurrence and metastases.
- the invention relates to a method for treatment of a cancer patient non-responsive to treatment with an immune checkpoint inhibitor (ICI), the method comprising administering to the cancer patient a therapeutically effective amount of the ICI along with a therapeutically effective amount of an agent that blocks the activity of a dominant factor, or of the receptor thereof, the dominant factor being selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, the plurality of host-driven resistance factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the ICI, wherein the fold change is established by comparing: (i) the level of each host-driven resistance factors in a blood sample selected from blood plasma, whole blood, blood serum or peripheral blood mononuclear cells, obtained from the cancer patient after a session of treatment with the ICI, with (ii) a reference level obtained for the same factor from a blood sample of the same type of (i), obtained from the cancer patient before said session of treatment with the ICI.
- ICI immune
- the blood samples of steps (i) and (ii) are both blood plasma.
- the session of treatment with the ICI is one of multiple sessions of treatment.
- the one of multiple sessions of treatment with the ICI is the first session of treatment with said ICI
- the blood sample of step (i) is obtained from the cancer patient at about 20, 24, 30, 36, 40, 48, 50, 60, 72 hours or more, including up to one week or more, up to two weeks or more or up to three weeks or more, after said first session of treatment
- the reference blood sample of step (ii) is obtained from the cancer patient at a time point including at about 72 hours or less, including at about 60, 50, 48, 40, 36, 30, 24 or 20 hours or less or just before said first session of treatment with the ICI.
- the one of multiple sessions of treatment of the cancer patient with the ICI is the first session of treatment, when the treatment with the ICI is started.
- the reference/baseline sample of step (ii), preferably blood plasma is obtained from the cancer patient at a time point before starting the treatment including at about 72 hours or less, including at about 60, 50, 48, 40, 36, 30, 24 or 20 hours or just before said first session of treatment with the ICI.
- the comparison is then made between the concentration levels of the factors determined in the blood sample, preferably blood plasma, obtained from the cancer patient at about 20, 24, 30, 36, 40, 48, 50, 60, 72 hours or more, including up to one week or more, up to two weeks or more, or up to three weeks or more, after said first session of treatment with the ICI.
- the blood sample preferably blood plasma
- the session of treatment of the cancer patient with the ICI is one of multiple sessions of treatment that is not the first session of treatment with the ICI.
- the blood sample is obtained from the cancer patient at any time point between two consecutive sessions of treatment with the ICI and serves simultaneously as the blood sample of step (i) and the reference blood sample according to step (ii) for the next session assay according to step (i).
- the time between two consecutive sessions of treatment depends on the treatment protocol approved for the specific ICI and may be, for example, of 2 or 3 weeks, depending on the ICI, and the blood sample may be obtained at day 1, 2, 3, 7, 14, or 21 days between two consecutive sessions.
- the levels of the plurality of factors generated by the host/cancer patient in response to the treatment with the immune checkpoint inhibitor are determined in the blood sample, preferably blood plasma, obtained from the patient after treatment with ICI.
- the value (factor concentration in pg/mL) obtained for each factor is then compared with a reference level, which is the baseline level of concentration of the same factor determined in a blood sample, preferably blood plasma, obtained previously from the same cancer patient (hereinafter “reference/baseline sample”).
- reference/baseline sample is the baseline level of concentration of the same factor determined in a blood sample, preferably blood plasma, obtained previously from the same cancer patient.
- the change in the level of one or more of the factors identified in the blood sample obtained from the cancer patient after the treatment with the ICI compared to the reference/baseline level is defined by the fold change for each factor.
- the fold change for each factor is determined by calculating the ratio of treatment: reference/baseline values for the factor.
- each of the one or more of the plurality of the host-driven resistance factors is considered significant and predictive of a non-favorable response of the cancer patient to the treatment with the ICI if its value is about 1.5 or higher denoting an up-regulation of the factor, or the fold-change is considered significant and predictive of a favorable response of the cancer patient to the treatment with said ICI if its value is about 0.5 or lower denoting down-regulation of the factor.
- the prediction of a favorable or a non-favorable response of the cancer patient to the treatment with an ICI is based on significant fold changes of one or more, optionally two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, fifteen or more, twenty or more, or twenty-five or more, of the host-driven resistance factors.
- the factors/biomarkers induced into the circulation of the cancer patient in response to treatment with the ICI include molecular factors such as cytokines, chemokines, growth factors, enzymes and soluble receptors.
- the factors may be pro-tumorigenic or pro-metastatic factors.
- the pro-tumorigenic factors may be pro-angiogenic, pro-inflammatory/chemotactic or proliferative growth factors.
- the session of treatment is the first session of a plurality of sessions of treatment of the cancer patient, when the treatment is started.
- the comparison is between the factors determined in the blood sample, preferably blood plasma, obtained from the cancer patient after first starting treatment with the ICI, and the same factors found in the reference/baseline blood sample, preferably blood plasma, obtained from the cancer patient before starting treatment with the ICI.
- the results may assist the medical oncologists treating the patient to decide if or how to continue the treatment of the cancer patient.
- the method of the invention is performed for monitoring treatment response in a cancer patient being treated with an ICI.
- the session of treatment is one of the sessions of several sessions of treatment, but not the first one. The results will assist the medical oncologist in their decisions if or how to continue the treatment.
- the fold change determined for pro-tumorigenic factors is predictive of the patient's favorable response to the cancer therapy and the decision may be to continue the treatment with the same ICI as scheduled.
- the fold change determined for pro-tumorigenic factors is predictive of the patient's non-favorable response to the ICI.
- the decision may be to continue the treatment with the same ICI but with the addition of a drug that blocks the biological activity of the tumorigenic factors, for example, by adding to the treatment an anti-inflammatory drug if the factors are pro-inflammatory or by adding to the treatment an anti-angiogenic drug if the factors are pro-angiogenic.
- Immune checkpoints are regulators of immune activation. They play a key role in maintaining immune homeostasis and preventing autoimmunity. In cancer, immune checkpoint mechanisms are often activated to suppress the nascent anti-tumor immune response. Immune checkpoint molecules are considered as good targets for cancer immunotherapy. Immune checkpoint inhibitors (ICI) that cause blockade of the immune checkpoint molecules are considered good candidates for the development of drugs for cancer immunotherapy with the potential for use in multiple types of cancers and are already in use or are under development.
- ICI Immune checkpoint inhibitors
- immune checkpoint inhibitor (ICI) drugs examples include PD-1 (Programmed Death-1) that has two ligands, PD-L1 and PD-L2; CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4); A2AR (Adenosine A2A receptor), also known as ADORA2A; BT-H3, also called CD276; BT-H4, also called VTCN1; BT-H5; BTLA (B and T Lymphocyte Attenuator), also called CD272; IDO (Indoleamine 2,3-dioxygenase); KIR (Killer-cell Immunoglobulin-like Receptor); LAG-3 (Lymphocyte Activation Gene-3); TDO (Tryptophan 2,3-dioxygenase); TIM-3 (T-cell Immunoglobulin domain and Mucin domain 3); VISTA (V-domain Ig suppressor of T cell activation).
- PD-1 Programmed Death-1
- the ICI is a monoclonal antibody (mAb) against PD-1 or PD-L1 that neutralizes/blocks the PD-1 pathway.
- the anti-PD-1 mAb is Pembrolizumab (Keytruda; formerly called lambrolizumab), approved or tested for treatment of advanced or unresectable melanoma, metastatic non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and recurrent squamous cell carcinoma of the head and neck (SCCH).
- the anti-PD-1 mAb is Nivolumab (Opdivo), approved or tested for NSCLC, RCC, melanoma and colorectal cancer (CRC).
- the anti-PD-1 mAb is Pidilizumab (CT0011), approved or tested for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia.
- CT0011 Pidilizumab
- the anti-PD-1 mAb is REGN2810, AMP-224, MEDI0680, or PDR001.
- the immune checkpoint inhibitor is a mAb against PD-L1.
- the anti-PD-L1 mAb is Atezolizumab (Tecentriq), Avelumab (Bavencio), or Durvalumab (Imfinzi), approved for multiple cancers.
- Atezolizumab is being tested in combination with one or two other cancer agents such as bevacizumab, gemcitabine, cisplatin, docetaxel, paclitaxel, vinflunine entinostat, daratumumab, MPDL3280A, carboplatin, Nab-paclitaxel, Radium-223 dichloride, obinutuzumab, for multiple cancers.
- the ICI is a mAb antibody against CTLA-4.
- the anti-CTLA-4 is Ipilimumab (Yervoy), approved or tested for advanced/metastatic melanoma and castrate-resistant prostate cancer.
- the anti-CTLA-4 mAb is Tremelimumab (formerly ticilimumab).
- the ICI is an inhibitor including: (i) anti-B7-H3, such as MGA271; (ii) anti-IDO, such as epacadostat; (iii) anti-KIR, such as Lirilumab; (iv) anti-LAG-3, such as Relatlimab (BMS-986016), LAG 525, REGN3767; (v) anti-TIM-3, such as TSR022 or MBG453; and (vi) anti-VISTA, such as JNJ 61610588.
- anti-B7-H3 such as MGA271
- anti-IDO such as epacadostat
- anti-KIR such as Lirilumab
- anti-LAG-3 such as Relatlimab (BMS-986016), LAG 525, REGN3767
- anti-TIM-3 such as TSR022 or MBG453
- anti-VISTA such as JNJ 61610588.
- a combination of two ICIs is used according to the invention.
- the combination comprises an anti-PD-1 and an anti-CTLA-4, e.g., Nivolumab-Ipilimumab and REGN2810-Ipilimumab.
- the combination comprises an anti-PD-L1 and an anti-CTLA-4, e.g., Durvalumab-Tremelimumab.
- the combination comprises an anti-PD-1 and an anti-PD-L1, e.g., Nivolumab-Atezolimumab.
- the combination comprises an anti-LAG-3 and an anti-PD-1, e.g., Relatlimab-Nivolumab or REGN3767-REGN2810.
- the combination comprises an anti-PD-1 and an MO inhibitor, e.g., Pembrolizurriab and Epacadostat and Nivolumab-Epacadostat.
- Costimulatory molecules such as CD137 (4-1BB), CD134 (OX40), glucocorticoid-induced TNFR (GITR; CD357), and CD40 are expressed by activated T cells, activated natural killer (NK) cells, natural killer T (NKT) cells, Tregs, and other immune cells.
- NK activated natural killer
- NKT natural killer T
- Tregs Tregs
- other immune cells The inhibition of the immune checkpoint PD-1 and stimulation of costimulatoiy molecules by agonist antibodies are complementary strategies to enhance immune responses and therefore provide a strong rationale for use in combination.
- the invention encompasses a combination of an ICI with an agonistic mAb against T-cell co-stimulatory molecules including an anti-ICOS mAb, e.g., MEDI-570 or BMS-986226; an anti-OX40 mAb e.g., MOXR0916, KHK4083, MEDI0562 or MEDI6469; an anti-CD40 mAb; and an anti-CD137 (4-IBB) mAb, e.g., Urelumab or Utomilumab.
- an anti-ICOS mAb e.g., MEDI-570 or BMS-986226
- an anti-OX40 mAb e.g., MOXR0916, KHK4083, MEDI0562 or MEDI6469
- an anti-CD40 mAb e.g., Urelumab or Utomilumab.
- the ICI is administered in combination with one or more conventional cancer therapy including chemotherapy, targeted cancer therapy and radiotherapy. Combinations of ICI and radiation therapy have been studied in multiple clinical trials.
- the ICI is used in combination chemotherapy that may be with a single or a combination of chemotherapy drugs, or metronomic chemotherapy.
- the ICI therapy is used in combination with targeted cancer therapy, sometimes called “molecularly targeted therapy”.
- the targeted therapy drugs are small molecules such as bortezomib (Velcade), sunitinib (Sutent).
- the targeted therapy drugs are monoclonal antibodies such as bevacizumab (Avastin), panitumumab (Vectibix), daratumumab (Darzalex).
- an anti-PD-1 is used in combination with sunitinib (Sutent) or pazopanib (Votrient) that was tested for treatment of RCC, or a combination of anti-CTLA-4 ipilimumab with BRAF inhibitor dabrafenib (Tafinlar).
- the ICI therapy is used in combination with anti-angiogenic therapy, for example, with a mAb that targets VEGF.
- the combination may be of Ipilimumab and bevacizumab.
- the ICI therapy is used in combination with other immunotherapies such as cancer vaccines, immunomodulators, immunostimulatory cytokines, e.g., GM-CSF, IFN- ⁇ , TGF- ⁇ , IL-10, IL-2, IL-15, IL-1.8, and IL-21, or oncolytic viruses.
- immunostimulatory cytokines e.g., GM-CSF, IFN- ⁇ , TGF- ⁇ , IL-10, IL-2, IL-15, IL-1.8, and IL-21
- oncolytic viruses e.g., anti-CTLA-4 ipilimumab or anti-PD-1 pembrolizumab is used in combination with oncolytic virus talimogene laherparepvec (I-VIE).
- the cancer therapy is related to all types of cancer, primary or metastatic, in all stages of the disease, including, but without being limited to, a primary or a metastatic cancer including bladder, bone, breast, brain, cervical, colon, colorectal, esophageal, gastric cancer, gastrointestinal, glioblastoma, head and neck, head and neck squamous cell cancer, hepatocellular cancer, kidney, liver, lung including small cell lung cancer and non-small cell lung cancer (NSCLC), melanoma, nasopharyngeal, ovarian, pancreas, penile, prostate, skin, testicular, thymus, thyroid, urogenital, or uterine cancer, leukemia, lymphoma, multiple myeloma and sarcoma.
- a primary or a metastatic cancer including bladder, bone, breast, brain, cervical, colon, colorectal, esophageal, gastric cancer, gastrointestinal, glioblastoma, head and
- the cancer is leukemia, a cancer of the body's blood-forming tissues, including the bone marrow and the lymphatic system.
- the leukemia is selected from acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) or chronic myeloid leukemia (CML).
- ALL acute lymphocytic leukemia
- AML acute myeloid leukemia
- CLL chronic lymphocytic leukemia
- CML chronic myeloid leukemia
- the cancer is multiple myeloma.
- the cancer is non-small cell lung cancer (NSCLC). In certain embodiments, the cancer is advanced (stage III or IV) or metastatic NSCLC.
- NSCLC non-small cell lung cancer
- advanced stage III or IV
- metastatic NSCLC metastatic NSCLC
- the cancer is metastatic melanoma, renal-cell carcinoma (RCC), classic Hodgkin's lymphoma (HL), bladder carcinoma, Merkel cell carcinoma, head and neck cancer, or solid tumors with mismatch repair-deficiency
- the host-driven factors/biomarkers identified by the method of the invention after administration of an immune checkpoint inhibitor to a cancer patient are specific to: (i) the cancer patient; and (ii) the immune checkpoint inhibitor.
- This is the “host response” that provides specific information about the cancer patient and allows the prediction in a personalized form to help diagnose, plan treatment, find out how well treatment is working, or make a prognosis
- the factors generated by the host/patient are specific to this particular ICI. If the treatment is carried out with a combination of two ICIs, the factors generated by the host/patient are specific to this combination of ICIs. If treatment is with the ICI in combination with another cancer therapy, the factors generated by the host/patient are specific to this combination.
- the biomarkers are molecular factors such as cytokines, chemokines, growth factors, enzymes or soluble receptors. Some of these factors induce cells that affect the tumor and contribute to tumor angiogenesis and cancer re-growth, thereby promoting resistance to the therapy used. Examples of such cells include bone-marrow derived cells (BMDCs) that are mobilized from the bone-marrow compartment by cytokines and growth factors such as G-CSF and SDF-1 ⁇ , and subsequently colonize the treated tumors and promote cancer therapy resistance, particularly, but not exclusively, chemotherapy resistance. Other cells are immune cells such as macrophages and antigen-presenting cells, or stromal cells within the tumor microenvironment which play a pivotal role in tumor progression.
- cytokines cytokines
- chemokines growth factors
- growth factors enzymes or soluble receptors.
- the host-mediated cellular and molecular mechanisms that contribute to tumor resistance to a cancer therapy are based on the biological functions of the factors and/or cells generated in the host by the particular cancer therapy. Each factor may exhibit one or more biological functions or activities.
- the factors are tumorigenic and contribute to tumor growth.
- the tumorigenic factors are pro-angiogenic.
- the tumorigenic factors are pro-inflammatory/chemotactic.
- the tumorigenic factors are proliferative growth factors.
- the pro-angiogenic factors include, without being limited to, ANG (angiogenin); angiopoietin-1; angiopoietin-2; bNGF (basic nerve growth factor); cathepsin S; Galectin-7; GCP-2 (granulocyte chemotactic protein, CXCL6); G-CSF (granulocyte-colony stimulating factor); GM-CSF (granulocyte-macrophage colony stimulating factor, also known as colony-stimulating factor 2, CSF2); PAI-1 (plasminogen activator Inhibitor-1); PDGF (platelet-derived growth factor) selected from PDGF-AA, PDGF-BB, PDGF-AB; P1GF (or PLGF, placental growth factor); P1GF-2; SCF (stem-cell factor); SDF-1(CXCL12, stromal cell-derived factor-1); Tie2 (or TIE-2, an endothelial receptor tyrosine kinase.
- the pro-inflammatory and/or chemotactic factors include, without being limited to, 6Ckine (CCL21, Exodus-2); angiopoietin-1; angiopoietin-2; BLC (CXCL13, B lymphocyte chemoattractant or B cell-attracting chemokine 1 (BCA-1); BRAK (CXCL14); CD186 (CXCR6); ENA-78 (CXCL5, Epithelial cell derived neutrophil activating peptide 78,); Eotaxin-1 (CCL11); Eotaxin-2 (CCL24); Eotaxin-3 (CCL26); EpCAM (Epithelial cell adhesion molecule); GDF-15 (growth differentiation factor 15, also known as macrophage inhibitory cytokine-1, MIC-1); GM-CSF; GRO (growth-regulated oncogene); HCC-4 (CCL16, human CC chemokine 4); I-309 (CCL1); IFN- ⁇ ; IL-1
- BLC
- the proliferative factors include, without being limited to, Activin A; Amphiregulin; Axl (AXL, a receptor tyrosine kinase); BDNF (Brain-derived neurotrophic factor); BMP4 (bone morphogenetic protein 4); cathepsin S; EGF (epidermal growth factor); FGF-1 (fibroblast growth factor 1); FGF-2 (also known as bFGF, basic FGF); FGF-7; FGF-21; Follistatin (FST); Galectin-7; Gas6 (growth arrest-specific gene 6); GDF-15; HB-EGF (heparin-binding EGF); HGF; IGFBP-1 (Insulin-like growth factor binding protein-1); IGFBP-3; LAP (Latency-associated peptide); NGF R (nerve growth factor receptor); NrCAM (neuronal cell adhesion molecule); NT-3 (neurotrophin-3); NT-4; PAI-1; TGF- ⁇ (transforming growth factor- ⁇ (
- the pro-metastatic factors include, without being limited to, ADAMTS1 (A disintegrin and metalloproteinase with thrombospondin motifs 1); cathepsin S; FGF-2; Follistatin (FST); Galectin-7; GCP-2; GDF-15; IGFBP-6; LIF; MMP-9 (Matrix metallopeptidase 9, also known as 92 kDa gelatinase or gelatinase B (GELB); pro-MMP9; RANTES (CCL5); SDF-1 (stromal cell-derived factor-1, also known as CXCL12) and its receptor CXCR4.
- ADAMTS1 A disintegrin and metalloproteinase with thrombospondin motifs 1
- cathepsin S FGF-2
- Follistatin FST
- Galectin-7 Galectin-7
- GCP-2 GDF-15
- IGFBP-6 LIF
- MMP-9 Microx metallopeptidase 9,
- the factors may also be anti-tumorigenic factors, e.g., anti-angiogenic, anti-inflammatory and/or anti-proliferative growth factors.
- the circulating factors indicating a host response to ICI include, but are not limited to, ADAMTS1, amphiregulin; Axl; CCL5/RANTES; CCL17/TARC; EGF; Eotaxin-2; FGF-21; Gas6; G-CSF; GM-CSF; HGF; IFN-gamma; IL-1Ralpha; IL-2; IL-6; IL-7; IL-10; IL-12p40; IL-13; IL-33; I-TAC; MadCAM-1; MCP-5; TACI; M-CSF; MMP-9; PDGF-BB; pro-MMP9; SCF.
- ADAMTS1 amphiregulin
- Axl include, but are not limited to, ADAMTS1, amphiregulin; Axl; CCL5/RANTES; CCL17/TARC; EGF; Eotaxin-2; FGF-21; Gas6; G-CSF; GM-CSF; HGF; IFN-gam
- Upregulated pro-angiogenic factors include: G-CSF; GM-CSF; and PDGF-BB.
- Up-regulated pro-inflammatory and/or chemotactic factors include: CCL17/TARC; CCL5/RANTES; G-CSF; GM-CSF; IFN-gamma; IL-1Ralpha; IL-2; IL-6; IL-7; IL-10; IL-12p40; IL-13; IL-33; and M-CSF.
- Upregulated proliferative growth factors include: FGF-21; Gash; and HGF.
- Upregulated pro-metastatic factors include: MMP-9.
- Upregulated pro-angiogenic factors include: G-CSF; and SCF.
- Upregulated pro-inflammatory and/or chemotactic factors include: Eotaxin-2; G-CSF; IL-1ra; IL-6; IL-7; IL-33; I-TAC; MadCAM-1; MCP-5; SCF; and TACI.
- Upregulated proliferative growth factors include: amphiregulin; Axl; EGF; and HGF.
- Upregulated pro-metastatic factors include: ADAMT S1 and pro-MMP9.
- the term “dominant factor” denotes a potent factor that may be upstream of a signaling pathway that affects a biological process that is vital for the living cell and living organism. These biological processes include proliferation, inflammation, metastasis, and others, and are made of several signaling pathways ultimately leading to activation or inhibition of the biological process.
- a “signaling pathway” is a row of events in which proteins in the same pathway transfer signal to each other. After the first protein in a pathway receives a signal, it activates another protein which activates another protein and so forth, ultimately leading to activation of one or more cell functions.
- a “dominant factor” may also be a key factor that highly interacts with, and highly affects, many other factors/proteins. According to the invention, the dominant factors are selected based on an algorithm which identifies the protein-protein interactions of factors based on the literature. When a factor has more interactions, it serves as a hub and therefore it is a dominant factor.
- the term “protein-protein interactions” refers to physical interactions or cross-talk between two or more proteins, resulting in activation or inhibition of signal transduction or protein activity.
- protein hubs refers to highly connected proteins that play central and essential role in biological processes and thus may confer the host with resistance, limit or counteract the effectiveness of the treatment of the cancer patient with the cancer therapy modality.
- block refers to the capability of an agent of preventing the selected dominant factor from exerting its function/biological activity.
- dominant factors include, without limitation, Amphiregulin, EGF, EGFR, FGF, IFN- ⁇ , IL-1 ⁇ , IL-2, IL-6, MMP-9, PDGF, TNF- ⁇ and VEGF-A.
- Interleukin-1 ⁇ (IL-1 ⁇ , IL-1b) is a cytokine member of the IL-1 family, produced by different immune cells including macrophages. It is a potent mediator of the inflammatory response and also known to be involved in several biological processes such as cell proliferation and apoptosis, as well as cell differentiation. IL-1b was mostly investigated as a protein that initiates the pro-inflammatory cascade.
- IL-1b serves as a hub for interactions with a large number of proteins that affect several biological pathways including cell proliferation, apoptosis and differentiation as well as inflammation and angiogenesis.
- Interleukin-6 is a cytokine that acts mainly as a pro-inflammatory factor but also sometimes as an anti-inflammatory factor produced by muscle cells and as a result downregulate a number of pro-inflammatory proteins such as IL-1, IL-10 and TNF- ⁇ .
- IL-6 is involved in a number of biological processes including bone formation, disruption of blood brain barrier, macrophage activation and innate immune system contribution, stimulates the synthesis of neutrophils and B cells, and is also involved in neurological activities such as disorders, stress and depression.
- IL6 interacts and affects a large number of proteins: it physically interacts with HRH1, OSM, IL6ST, IL6R and ZBTB16, and was found to be co-expressed with a large number of proteins such as PTPRE, CSF3, CCL2, CXCL8, CXCL3, ICAM1 SELE, NFKBIZ among others.
- IL6 is involved in a number of pathways mediated by proteins such as LRPPRC, OSM, PTPRE, PIAS1 and IL6R. As such, IL6 serves as a dominant factor for a number of biological processes involved in immune cell activity, cell genesis, and cell-cell interactions.
- VEGF-A vascular endothelial growth factor A
- angiogenesis endothelial cell proliferation
- vasculogenesis bone marrow-derived endothelial cell precursors and their differentiation
- VEGF is important for embryonic cell development and neuronal development in the fetus, and is involved in leukocyte proliferation and differentiation, inflammation and several diseases such as age-related macular degeneration and the majority of cancers.
- VEGF-A physically interacts with a large number of proteins such as NRP1, NRP2, KDR, FLT1, PGF, THBS1, SPARC, GCP1 and VEGFC; it is co-expressed with SEMA3F, SHB, THBS1, FLT1 and VEGFC; it is involved with proteins of various pathways including PGF, CD2AP, IQGAP1, NEDD4; and it affects a number of biological processes such as angiogenesis, tumorigenesis, cell viability, proliferation and differentiation. As such, VEGF-A is considered a dominant factor, and vital factor for various biological processes both in normal physiological conditions as well as in disease states.
- the selected dominant factor shows a fold change of ⁇ 1.5 indicative of a non-favorable response of the cancer patient to the treatment with the ICI
- the treatment of the patient with said ICI may proceed in combination with an agent that blocks said dominant factor or the receptor thereof.
- the dominant factor is selected from factors including amphiregulin, EGF, EGFR, FGF, IFN- ⁇ , IL-1 ⁇ , IL-2, IL-6, MMP9, PDGF, TNF- ⁇ and VEGF-A.
- the dominant factor is MMP9
- the ICI is an anti-PD-1 or anti-PD-L1 monoclonal antibody
- the cancer patient is treated with the ICI in combination with a MMP-9 inhibitor including SB-3CT.
- the dominant factor is amphiregulin
- the ICI is an anti-PD-1 or anti-PD-L1 monoclonal antibody
- the cancer patient is treated with the ICI in combination with an anti-amphiregulin antibody.
- CT26 colon and EMT-6 breast carcinoma cell lines respond to anti-CTLA-4 and anti-PD-L1, respectively (Duraiswamy et al., 2013; Swart et a., 2013), whereas MC38 colon and 4T1 breast carcinoma cell lines are resistant or only modestly responsive to some ICIs (including anti-PD-1) (De Henau et al., 2016; Kodumudi et al., 2016), as also tested in our laboratory (not shown).
- Anti-amphiregulin (cat. #AF989) was purchased from R&D systems. A 10 mM stock solution of SB-3CT was prepared in 100% DMSO (Sigma). For in-vivo experiment, the stock solution was diluted to a final concentration of 1.25 mg/ml in 10% DMSO in normal saline.
- Murine EMT6 breast carcinoma and CT26 murine colon carcinoma cells were purchased from the American Type Culture Collection (ATCC, USA). The cells were used in culture for no more than 4 months after being thawed from authentic stocks and were regularly tested and found to be mycoplasma -free (EZ-PCR mycoplasma test kit, Biological Industries, Israel). EMT6 Cells were cultured in Dulbecco's modified eagle medium (DMEM) and CT26 cells were cultured in RPMI 1640 medium, both supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, 1% sodium-pyruvate and 1% penicillin-streptomycin (Biological Industries, Israel). Cells were cultured at 37° C. in 5% CO 2 .
- DMEM Dulbecco's modified eagle medium
- CT26 cells were cultured in RPMI 1640 medium, both supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, 1% sodium-pyru
- mice Na ⁇ ve 8-10 week old female BALB/c, SCID or NOD-SCID mice (Harlan, Israel) were used in this study. Experiments were performed in accordance with the Animal Ethic Committee at the Technion (Haifa, Israel). The mice were intraperitoneally injected with anti-PD-1 or irrelevant IgG rat-anti-mouse antibodies (BioXCell, West Riverside, N.H., USA).
- mice nave 8-10-week old female and male BALB/c or C57bl/6 mice (Harlan, Israel) were intraperitoneally injected with anti-PD-L1 or irrelevant IgG rat-anti-mouse antibodies (BioXCell, West Riverside, N.H., USA). In all cases, antibodies were administered at a dose of 200 ⁇ g/20 gr mouse, every other day over the period of 1 week (3 injections in total).
- EMT6 murine breast carcinoma cells (5 ⁇ 10 5 ) were orthotopically implanted into the mammary fat pad of 8-10-week old BALB/c mice. Tumor size was assessed regularly with Vernier calipers using the formula width 2 ⁇ length ⁇ 0.5. In some experiments, mice were injected through the tail vein with EMT6 cells (25 ⁇ 10 3 ) to form experimental lung metastasis. Mouse survival was monitored daily.
- EMT6 GFP murine breast carcinoma cells a highly selective metastatic clone, called EMT6-F2, previously described for other cell line in Munoz et al., 2006
- EMT6-F2 highly selective metastatic clone, called EMT6-F2
- mice were IP injected with 200 ⁇ g anti-PD-L1, 50 ⁇ g SB-3CT (a MMP-2/MMP-9 selective inhibitor) (Kruger A., 2005, Bonfil R D., 2006); or a combination of anti-PD-L1 and SB-3CT.
- mice or mice treated with anti-PD-L1 monotherapy were injected with vehicle control (25% DMSO/65% PEG-200/10% PBS). Tumor growth and mouse survival were monitored and at endpoint (when tumors reached a size of 1500 mm 3 , or maximum at day 27), mice were sacrificed.
- CT26 cells were subcutaneously implanted in the right flank of 8-10 weeks old BALB/c mice.
- tumors reached a size of 50 mm 3
- mice were IP injected with 200 ⁇ g anti-PD-L1, 5 ⁇ g anti-AREG (as previously demonstrated in Fujiu K., 2017) or a combination of anti-PD-L1 and anti-AREG, every 3 days. Control mice were left untreated. Tumor growth and mouse survival were monitored.
- ELISA IL-6 mouse ELISA Kit, 100712 Abcam
- Plasma samples from control IgG-, anti-PD-1-, or anti-PD-L1-treated mice were collected into EDTA-coated tubes by cardiac puncture. Subsequently, plasma was isolated by centrifugation of whole blood at 1000 g, 4° C., for 20 min. Plasma was stored in aliquots at ⁇ 80° C. until further use. Bone marrow derived cells were flushed from the femurs of IgG or anti-PD-1 treated mice. Bone marrow cells (1 ⁇ 10 6 cells/ml) were cultured in serum-free DMEM for 24 hours to generate conditioned medium (CM).
- CM conditioned medium
- Samples were applied to a glass slide-based Quantibody Mouse Cytokine Array (RayBiotech, Cat no: QAM-CAA-4000) according to the manufacturer's instruction to screen a total of 200 factors.
- Samples were applied to a glass slide-based Quantibody Mouse Cytokine Array (RayBiotech, Cat no: QAM-CAA-4000) according to the manufacturer's instruction to screen a total of 200 factors.
- pixel densities on developed X-ray films were analyzed using transmission mode densitometer and image analysis software.
- the fluorescent readout was detected by a laser fluorescent scanner. In all cases, data was normalized and the fold changes for each factor on the arrays were determined by calculating the ratio of treated: control values.
- SD mean ⁇ standard deviation
- the statistical significance of differences was assessed by one-way ANOVA, followed by Tukey ad hoc statistical test using GraphPad Prism 5 software (La Jolla, Calif.). Student t-test was used in some experiments when comparing only two groups. Differences between all groups were compared with each other. For the IL-6 quantification by ELISA, the statistical significance of differences was assessed by two tailed unpaired T-test. For tumor growth experiments, statistical significance is assessed by multiple T-test. For survival analysis, differences are assessed by Log-rank Mantle-Cox. Differences were considered significant at p values below 0.05.
- na ⁇ ve mice non-tumor bearing mice. The use of na ⁇ ve mice allows us to identify factors specifically generated by the host in response to therapy, independent of the tumor.
- anti-PD-1 rat anti-mouse antibody BioXCell, West Riverside, N.H., USA
- Plasma samples were applied to a membrane-based Proteome Profiler Mouse XL Cytokine Array (R&D Systems; Cat no: ARY028) to screen a total of 111 factors.
- a full list of cytokines, enzymes and growth factors detected by the array is shown in Table 1.
- Pixel densities on developed X-ray films were analyzed using transmission mode densitometer and image analysis software. Normalized data was analyzed to identify factors whose circulating levels were changed in response to anti-PD-1 treatment. Specifically, the fold change was determined for each factor by calculating the ratio of treatment: control values.
- Factors exhibiting a fold change of more than 1.5 or less than 0.5 were defined as being up- or down-regulated, respectively, in response to anti-PD-1 treatment. These factors and their respective fold changes are listed in Table 2. Many of the factors that were upregulated in response to anti-PD-1 treatment are key players in pro-tumorigenic and pro-metastatic processes such as angiogenesis, inflammation, chemotaxis and proliferation. Upregulated pro-angiogenic factors include: G-CSF; GM-CSF; and PDGF-BB.
- Up-regulated pro-inflammatory and/or chemotactic factors include: CCL17/TARC; CCL5/RANTES; G-CSF; GM-CSF; IFN-gamma; IL-1Ralpha; IL-2; IL-6; IL-7; IL-10; IL-12p40; IL-13; IL-33; and M-CSF.
- Upregulated proliferative growth factors include: FGF-21; Gash; and HGF.
- Upregulated pro-metastatic factors include: MMP-9.
- cytokines, enzymes and growth factors detected by the array is shown in Table 3.
- the fold changes were determined for each factor on the protein array by calculating the ratio of treated: control values. Factors exhibiting a fold change of more than 1.5 or less than 0.5 were defined as being up- or down-regulated, respectively, in response to anti-PD-L1 treatment. These factors, and their respective fold changes are listed in Table 4.
- Table 4 The data demonstrate that the profiles of up- and down-regulated factors do not completely overlap when comparing between the different mouse strains or when comparing between males and females of the same strain. This suggests that the response to anti-PD-L1 treatment is genotype-dependent.
- Upregulated pro-angiogenic factors include: G-CSF; and SCF.
- Upregulated pro-inflammatory and/or chemotactic factors include: Eotaxin-2; G-CSF; IL-1ra; IL-6; IL-7; IL-33; I-TAC; MadCAM-1; MCP-5; SCF; and TACI.
- Upregulated proliferative growth factors include: amphiregulin; Axl; EGF; and HGF.
- Upregulated pro-metastatic factors include: ADAMTS1 and pro-MMP9.
- SCID mice carry the severe combined immune deficiency (SCID) mutation on the BALB/c background, and therefore lack functional adaptive immune cell types (B cells and T cells).
- SCID mice carry the severe combined immune deficiency (SCID) mutation on the BALB/c background, and therefore lack functional adaptive immune cell types (B cells and T cells).
- mice Twenty-four hours after the last administration, mice were sacrificed, blood was drawn and plasma was prepared. Plasma samples from each group were pooled and applied to a glass slide-based Quantibody Mouse Cytokine Array (RayBiotech, Cat no: QAM-CAA-4000) according to the manufacturer's instruction to screen a total of 200 factors.
- a full list of cytokines, enzymes and growth factors detected by the array is shown in Table 3.
- the fold changes were determined for each factor on the protein array by calculating the ratio of treated: control values. Factors exhibiting a fold change of more than 1.5 or less than 0.5 were defined as being up- or down-regulated, respectively, in response to anti-PD-1 treatment. These factors, and their respective fold changes are listed in Table 5.
- Matrix metallopeptidase 9 is an enzyme that belongs to the zinc-metalloproteinases family involved in the degradation of the extracellular matrix. MMP-9 is involved in a variety of biological processes, among them are pro-tumorigenic and tissue regeneration biological processes, including epithelial to mesenchymal transition, cell proliferation, angiogenesis, bone formation and wound healing. MMP-9 is one of the key factors involved in invasion and metastasis. Due to its involvement in various key dominant biological pathways in cancer, for which drugs have been developed as anti-cancer agents, MMP-9 serves as a dominant factor induced in response to ICI therapy, and whose inhibition may improve therapeutic outcome.
- MMP-9 was found to be induced in BALB/c mice following treatment with anti-PD-1 or anti-PD-L1, which demonstrate that: i) MMP-9 is secreted by bone marrow-derived cells of na ⁇ ve BALB/c mice in response to anti-PD-1 treatment; ii) the plasma level of MMP9 is increased 5.4 fold in response to anti-PD-1 treatment in na ⁇ ve BALB/c mice (Table 2); and iii) the plasma level of pro-MMP-9 is increased by 2-3 fold in response to anti-PD-L1 treatment in na ⁇ ve BALB/c mice (Table 4).
- the MMP2/MMP9 selective inhibitor SB-3CT is used in combination with anti-PD-1 or anti-PD-L1 antibodies.
- EMT6 murine breast carcinoma cells (5 ⁇ 10 5 ) are orthotopically implanted in the mammary fat pad of BALB/c mice, age 8-weeks, (Harlan, Israel). Tumor size is assessed regularly with Vernier calipers using the formula width 2 ⁇ length ⁇ 0.5.
- Anti-PD-1, anti-PD-L1 and IgG control antibodies are administered by intraperitoneal injections at a dose of 200 ⁇ g/20 g mouse every 3 days.
- SB-3CT is administered by intraperitoneal injections at a dose of 1 mg/20 g mouse every 3 days.
- mice are injected with IgG antibody and vehicle (10% DMSO in normal saline).
- Mice receiving either anti-PD-1 or anti-PD-L1 monotherapies are also injected with vehicle (10% DMSO in normal saline).
- Mice receiving SB3-CT monotherapy are also injected with IgG control antibodies. Tumor growth and mouse survival are monitored. At endpoint (when tumors reach a size of ⁇ 1500 mm 3 or until experiment reached 27 days), mice are sacrificed.
- mice treated with a combination of anti-PD-L1 and the MMP-2/MMP-9 inhibitor SB-3CT exhibited reduced tumor size compared to mice treated with vehicle, anti-PD-L1 or SB-3CT alone.
- the advantage of the combined treatment over treatment with the anti-PD-L1 alone was demonstrated by better response rate in individual mice ( FIG. 1C , black versus grey, respectively), where it is clearly shown that 3 out of the 8 mice treated with the combined treatment demonstrated reduced tumor size at end point (day 27) compared to the other mice.
- FIG. 1D not only the combined treatment inhibited tumor growth, but also improved mice survival.
- mice treated with the combination therapy exhibited increased survival compared to the control mice, mice treated with anti-PD-L1 or mice treated with SB-3CT.
- Amphiregulin is one of the ligands of the epidermal growth factor receptor (EGFR). Studies have demonstrated a functional role of amphiregulin in several aspects of tumorigenesis. Amphiregulin was chosen in light of our findings described in Example 1 above, which demonstrate that the plasma levels of amphiregulin are increased 2-3 fold in response to anti-PD-L1 treatment in na ⁇ ve BALB/c and C57/bl/6 mice (Table 4), and 3.7 fold in response to anti-PD-1 treatment in BALB/c mice (Table 5).
- EGFR epidermal growth factor receptor
- Amphiregulin is known to be involved in number of biological processes crucial for tumor development such as proliferation, invasion, angiogenesis, metastasis and resistance to apoptosis, proposing that its expression is indicative of non-responsiveness to cancer treatment. Moreover, Amphiregulin is one of the ligands of an important cancer promoting receptor, Epidermal Growth Factor Receptor (EGFR). As such, it is considered a dominant factor with pro-tumorigenic activities, and its inhibition may improve treatment efficacy.
- EGFR Epidermal Growth Factor Receptor
- CT26 colon carcinoma cells were subcutaneously implanted into BALB/c mice. When tumors reached a size of 50 mm 3 , mice were either treated with anti-PD-L1, anti-AREG or anti-PD-L1 and anti-AREG combination therapy while control mice were left untreated. Tumor growth and mouse survival were monitored.
- FIG. 2A As demonstrated in FIG. 2A , treatment with anti-AREG in combination with anti-PD-L1, exhibited lower tumor growth compared to control mice and anti-AREG-treated mice. While no major difference between the average tumor volume of mice treated with the combined therapy and the anti-PD-L1 was observed, the combined therapy demonstrated a complete response (disappearance of the tumors) in 25% of the treated mice while none of the mice treated with anti-PD-L1 demonstrated this phenomenon ( FIG. 2B ; The dashed vertical lines represent the days of treatment administration). The higher efficacy of the combined treatment is directly correlated with mice survival ( FIG. 2C ). Accordingly, mice treated with the amphiregulin inhibitor in combination with anti-PD-L1 have indicated better survival rates compared to control mice, mice treated with anti-PD-L1 or mice treated with anti-AREG monotherapy.
- Example 4 IL-6 Expression is Induced in Response to ICI Treatment
- IL-6 is another dominant factor that was demonstrated above to be highly induced in response to ICI therapy. As presented, IL-6 was increased by 15.6-fold in response to anti-PD-1 treatment in BALB/c mice (Table 2), 1.7-1.8-fold in response to anti-PD-L1 treatment in nave BALB/c and C57/bl/6 mice (Table 4) and 1.8-fold in response to anti-PD-1 treatment in SCID mice (Table 5).
- mice injected with anti-PD-L1, anti-CTLA-4 or untreated (control mice) were analyzed for IL-6 level in the plasma using ELISA (IL-6 mouse ELISA Kit, ab 100712, Abcam).
- IL-6 mouse ELISA Kit IL-6 mouse ELISA Kit, ab 100712, Abcam.
- mice treated with anti-PD-L1 and anti-CTLA-4 exhibited a pronounced induction of IL-6 concentration (13.4 and 6.15 pg/ml, respectively) compared to control mice in which IL-6 was undetectable (p values 0.03 and 0.02, respectively). Since this experiment was performed using nave mice, it demonstrates that IL-6 is produced by host cells in response to immune checkpoint inhibitors therapy, independently of tumor presence.
- IL-6 is known to be involved in number of biological processes crucial for tumor development including proliferation, angiogenesis, inflammation, differentiation and resistance to apoptosis.
- IL-6 is a pro-inflammatory cytokine that have been described as a prognostic factor in cancer. Since IL-6 is located at the top of the pro-inflammatory cascade and have been demonstrated to correlate with metastasis it is considered as a dominant factor with pro-tumorigenic and pro-metastatic activities.
- mice were subcutaneously injected with CT26 murine colon carcinoma cells. When tumors reached a size of 50 mm 3 , mice were IP injected with anti-PD-L1, anti-IL-6, or a combination of the two antibodies and control mice were left untreated. Tumors growth was monitored regularly and when reached a size of 2000 mm 3 mice were sacrificed. As demonstrated in FIG. 5A , mice treated with the combination of anti-PD-L1 and anti-IL-6 exhibited reduced tumor growth compared to control, anti-PD-L1 or anti-IL-6 treated mice (p values of 0.003, 0.192 and 0.009, respectively).
- the combined treatment with anti-PD-L1 and anti-IL-6 not only reduced tumor growth but also improved mice survival (undefined median survival) compared to control, anti-PD-L1 or anti-IL-6 treatments (median survival of 31, 39.5 and 31 days, respectively) (p values 0.0026, 0.3552 and 0.0386, respectively), with about 70% survival after 40 days, compared to 50% for the anti-PD-L1 alone group.
- mice were orthotopically injected with EMT6 murine breast carcinoma cells into the mammary fat pad.
- tumors reached a size of 100 mm 3
- mice were IP injected with anti-CTLA-4, anti-IL-6 or a combination of anti-CTLA-4 and anti-IL-6 once every three days (a total of 4 injections).
- Control mice were left untreated. Tumor growth was monitored regularly and when a size of 1500 mm 3 was reached, mice were sacrificed.
- FIG. 5A clearly demonstrates enhanced anti-tumor effect of the combined treatment (anti-CTLA-4 and anti-IL-6) compared to the control, anti-CTLA-4 alone or anti-IL-6 treated mice (p values 0.002, 0.137 and ⁇ 0.001 respectively). Moreover, three out of five mice (60%) treated with the combined treatment of anti-CTLA-4 and anti-IL-6 showed complete response to the treatment and their tumors completely disappeared at about day 35, in contrast to one mouse in the anti-CTLA-4 group, showing that the combined treatment not only inhibited tumor growth but also eradicated the tumor.
- Blocking host-derived IL-6 in combination with anti-CTLA-4 also improved mice survival. As shown in FIG. 5B , mice treated with anti-CTLA-4 in combination with anti-IL-6 exhibited enhanced survival rate (undefined median survival) compared to mice treated with anti-CTLA-4, anti-IL-6 or control mice (median survival of 49, 27 and 27 days, respectively), p values 0.076, 0.0008 and 0.0005, respectively.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Primary Health Care (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
Abstract
Description
- This application claims the benefit of priority of non-provisional U.S. application Ser. No. 16/219,203, filed on Dec. 13, 2018. The disclosure of the prior application is considered part of and is incorporated by reference in its entirety in the disclosure of this application.
- The present invention is in the field of oncology and particularly relates to a method of treatment of a cancer patient with an immune checkpoint inhibitor in combination with another therapeutic agent.
- One of the major obstacles in clinical oncology is that tumors often develop resistance to therapy even when an initial tumor response to treatment is observed. Many studies have focused on the contribution of mutations and genetic aberrations in the tumor cells which promote drug resistance and can explain tumor re-growth. However, studies have demonstrated that the host, in response to cancer therapy, generates pro-tumorigenic and pro-metastatic effects which in turn contribute to tumor re-growth, and therefore negate the anti-tumor activity of the drug (for reviews see Katz and Shaked, 2015; Shaked, 2016).
- Host-mediated responses to anti-cancer treatment modalities may be molecular and/or cellular responses. Upon treatment with chemotherapeutic drugs, host bone marrow derived cells (BMDCs) are mobilized from the bone marrow compartment, colonize the treated tumor and contribute to tumor angiogenesis and cancer re-growth, thereby promoting therapy resistance (Shaked et al., 2006, 2008). Cancer therapy also induces pro-tumorigenic activation of various immune cells such as macrophages and antigen presenting cells (Beyar-Katz et al., 2016; De Palma and Lewis, 2013; Kim et al. 2012; Ma et al., 2013). Overall, these aforementioned studies indicate that host-mediated molecular and cellular responses to different anti-cancer treatments involve the activation or education of immune cells as well as the secretion of various pro-tumorigenic factors. These combined effects contribute to tumor re-growth and resistance to therapy. This relatively new phenomenon has made a paradigm shift in understanding cancer progression and resistance to cancer therapy.
- Recently, a new treatment modality, an immunotherapy using immune checkpoint inhibitors (ICIs), is revolutionizing cancer therapy. Such immune-modulating drugs have shown remarkable successes for the treatment of advanced malignancies (including stage IV) such as melanoma, prostate, non-small cell lung cancer, renal cell carcinoma and also some hematological malignancies (Postow et al., 2015). Although the human immune system is capable of recognizing and mounting a response to cancerous cells, this response is often circumvented by tumor-derived inhibition resulting in immune tolerance. In this regard, tumor-infiltrating lymphocytes (TILs), such as tumor antigen-specific CD8+ cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, have been found to colonize the tumor microenvironment (Gajewski et al., 2013). Yet, at the tumor site, they completely lack the ability to act against tumor cells (Ostrand-Rosenberg and Sinha, 2009). This is due to direct inhibitory effects of factors secreted by cancer cells, stromal cells or other suppressive immune cells such as myeloid derived suppressor cells (MDSCs) and T regulatory cells (Tregs) (Makkouk and Weiner, 2015). For instance, IL-10 is frequently upregulated in various types of cancer, and was shown to suppress the immune system (Sato et al., 2011). Thus, identifying molecules that negatively regulate the immune system against tumor cells, will lead to the development of immunomodulatory drugs that support the activation of immune cells against tumors.
- Of specific interest are immune checkpoint proteins, such as CTLA-4, PD-1 and its ligand, PD-L1. These checkpoint proteins are expressed by tumor cells or other immune cells and contribute to the exhaustion of CTLs (Postow et al., 2015; Topalian et al., 2015). Specifically, they keep immune responses in check, and inhibit T cell killing effects against tumor cells. As such, checkpoint inhibitors have been developed in order to inhibit the immune suppression effects. Currently, antibodies blocking the immune checkpoints CTLA-4 and PD-1 or its ligand PD-L1 have been developed (Pardoll, 2012). These ICIs are currently in use in the clinic for the treatment of various malignancies with some promising and remarkable successes (Romano and Romero, 2015). However, ICIs have shown therapeutic benefit only for a limited portion of cancer patients (˜10-20%). For example, pooled data from clinical studies of ipilimumab, a CTLA-4 blocking antibody, revealed that the duration of clinical response is around 3 years, and can last up to 10 years. However, this dramatic therapeutic effect is only observed in a subset of patients (˜20%). Thus, the majority of patients exhibit intrinsic resistance mechanisms to such therapies. Yet, the molecular aspects that define the subpopulation of patients that are responsive to ICIs are not fully clear. It has been suggested that markers such as PD-L1 expression by tumor cells, mutational burden, and lymphocytic infiltrates could predict the cancer patients that will respond to ICI immunotherapy. However, these aforementioned biomarkers do not always correlate with tumor responsiveness to ICI immunotherapy or resistance of patients to ICIs. Therefore, additional possible mechanisms are still unknown.
- In the Applicant's International Patent Applications No. PCT/IL2018/050608 and No. PCT/IL2018/050609, both filed on Jun. 4, 2018 and published as WO2018/225062 and WO 2018/225063, respectively, the entire contents of which are hereby incorporated herein by reference, a method of predicting personalized response to cancer treatment with a cancer therapy was described by identification of a plurality of factors/biomarkers induced by the cancer patient into the circulation in response to said cancer therapy (“host response”) and determining how a change in the levels of each of one or more of the plurality of factors as compared to a reference level, predicts a favorable or a non-favorable response of the cancer patient to the treatment with said cancer therapy.
- It would be highly desirable to unveil host-mediated cellular and molecular mechanisms that contribute to tumor resistance to all modalities of cancer therapy including the promising ICI immunotherapy modality. This will permit development of strategies to block such unwanted host effects and will improve therapeutic outcome and delay resistance to cancer therapy.
- The present invention is based on previous studies mentioned hereinbefore in the Background section of the application that show that a cancer patient (the “host”), in response to a cancer therapy, may generate and induce into the host circulation a set of host-driven resistance factors to cancer immunotherapy with an immune checkpoint inhibitor (hereinafter “ICI”), that may limit or counteract the effectiveness of the patient treatment with the ICI. The determination of these factors allows the prediction in a personalized form of the favorable or non-favorable response of the patient to the treatment with the ICI. These factors, herein designated interchangeably “factors” or “biomarkers”, are factors, mainly cytokines, chemokines, growth factors, soluble receptors, enzymes and other molecules produced by the host cells, either at different organs or at the tumor microenvironment, in response to the cancer therapy with the ICI with which the patient is treated.
- Thus, in one aspect, the present invention provides a method of treating a cancer patient with an immune checkpoint inhibitor (ICI), the method comprising the steps of:
- (i) performing an assay on a blood sample selected from blood plasma, whole blood, blood serum or peripheral blood mononuclear cells obtained from the cancer patient at a time point after a session of treatment with said ICI, to determine the levels of one or more of a plurality of host-driven resistance factors that are driven by the host (“the cancer patient”) in response to treatment with the ICI, said one or more of the plurality of factors promoting in a personalized form responsiveness or non-responsiveness of the cancer patient to the treatment with the ICI;
- (ii) obtaining reference levels for each of the one or more of the plurality of the host-driven resistance factors of step (i) by determining the levels of each of said factors in a blood sample of the same type of the blood sample of step (i), obtained from the cancer patient at a time point before said session of treatment with the ICI;
- (iii) establishing the fold change for each of the one or more of the plurality of the host-driven resistance factors of step (i) by comparing the level of each host-driven resistance factor of step (i) with the reference level of step (ii) for the same factor;
- (iv) determining that the cancer patient has a favorable or a non-favorable response to the treatment with said ICI based on the fold change established in step (iii) for one or more of the plurality of host-driven resistance factors of step (i); and
- (iva) if the cancer patient has a non-favorable response to the treatment with said ICI based on the fold change established in step (iii) for one or more of the plurality of the host-driven resistance factors, then selecting a dominant factor among the one or more host-driven resistance factors showing a fold change indicative of said non-favorable response, and treating the patient with a therapeutically effective amount of the ICI along with a therapeutically effective amount of an agent that blocks the activity of the selected dominant host-driven resistance factor (herein “the dominant factor”) or the receptor thereof; or
- (ivb) if the cancer patient has a favorable response to the treatment with said ICI based on the fold change established in (iii) for one or more of the plurality of host-driven resistance factors, then continuing the treatment of the cancer patient with the ICI alone.
- In a certain embodiment, the invention relates to a method for treatment of a cancer patient non-responsive to treatment with an immune checkpoint inhibitor (ICI), the method comprising administering to the cancer patient a therapeutically effective amount of the ICI in combination with a therapeutically effective amount of an agent that blocks the activity of a dominant factor, or of the receptor thereof, the dominant factor being selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, the plurality of host-driven resistance factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the ICI, wherein the fold change is established by comparing: (i) the level of each host-driven resistance factors in a blood sample selected from blood plasma, whole blood, blood serum or peripheral blood mononuclear cells, obtained from the cancer patient after a session of treatment with the ICI, with (ii) a reference level obtained for the same factor from a blood sample of the same type of (i), obtained from the cancer patient before said session of treatment with the ICI. Preferably, the blood samples of steps (i) and (ii) are both blood plasma.
- In another aspect, the present invention relates to an immune checkpoint inhibitor (ICI), for use in the treatment of cancer in a patient non-responsive to said treatment, comprising administering a therapeutically effective amount of the ICI in combination with a therapeutically effective amount of an agent that blocks the activity of a dominant factor, or of the receptor thereof, the dominant factor being selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, the plurality of host-driven resistance factors having a fold-change predictive of a non-favorable response of the cancer epatient to the treatment with the ICI, wherein the fold change is established by comparing: (i) the level of each host-driven resistance factor in a blood sample selected from blood plasma, whole blood, blood serum or peripheral blood mononuclear cells, obtained from the cancer patient after a session of treatment with the ICI, with (ii) a reference level obtained for the same factor from a blood sample of the same type of (i), obtained from the cancer patient before said session of treatment with the ICI. Preferably, the blood samples of steps (i) and (ii) are both blood plasma.
-
FIGS. 1A-1D show the effect of blocking MMP9 on primary tumor growth and survival in a mouse model of breast cancer.FIG. 1A shows that mice treated with a combination of anti-PD-L1 and the MMP-2/MMP-9 inhibitor SB-3CT exhibit reduced tumor size compared to mice treated with vehicle, anti-PD-L1 or SB-3CT alone.FIG. 1B shows tumor volume atday 27, the last experimental day.FIG. 1C shows better response rate and reduced tumor size for individual mice treated with the combined therapy compared to anti-PD-L1 alone.FIG. 1D shows better survival of mice treated with the combined therapy compared to the other treatment groups. -
FIGS. 2A-2C show the effect of blocking host-derived amphiregulin on primary tumor growth and survival in a mouse model of colon cancer.FIGS. 2A-2B show tumor volume of mice treated with anti-PD-L1, anti-amphiregulin antibody (anti-AREG) or anti-PD-L1 and anti-AREG combined therapy.FIG. 2C is a Kaplan-Meier curve demonstrating better survival of mice treated with the combined therapy compared to the other treatment groups. -
FIG. 3 shows IL-6 expression following treatment with anti-PD-L1 or anti-CTLA-4. -
FIGS. 4A-4C show the effect of blocking host-derived IL-6 induced following treatment with anti-PD-L1 on primary tumor growth and mice survival.FIG. 4A shows inhibition in tumor growth in mice treated with a combination of anti-PD-L1 and anti-IL-6 compared to control mice or mice treated with either anti-PD-L1 or anti-IL-6 alone.FIG. 4B corresponds toFIG. 4A , but shows tumor growth in individual animals, andFIG. 4C shows that combined treatment with both anti-PD-L1 and anti-IL-6 also led to better survival relative to the other treatment groups. -
FIGS. 5A-5B show the effect of blocking host-derived IL-6 induced following treatment with anti-CTLA-4 on primary tumor growth and survival. Treatment of BALB/c mice with anti-CTLA-4 resulted in reduced tumor growth (FIG. 5A ) and better survival relative to control mice (FIG. 5B ), and these effects were further improved by combined treatment with both anti-CTLA-4 and anti-IL-6 antibodies (FIGS. 5A-5B ). - Before describing the methods of the invention, it should be understood that this invention is not limited to the particular methodology and protocols as described herein. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only and, if not defined otherwise, it is not intended to limit the scope of the present invention which will be recited in the appended claims.
- It must also be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise.
- As used herein, the term “a cancer therapy” may be used interchangeably with the term “a “a cancer-modality therapy”, and include plural reference, namely, one single modality therapy or a combination of two or more modality therapies.
- As used herein, the terms “induced”, “driven” and “generated” are used interchangeably to denote the factors induced into the circulation by the cancer patient in response to the cancer therapy (“host-response”).
- In cancer therapy, a cycle of treatment means that the drug is administered to the patient at one point in time (for example, injections over a day or two) and then there is some time (e.g., 1, 2 or 3 weeks) with no treatment. As used herein, “a session of treatment” refers to the “one point in time” when the ICI is administered to the patient at the beginning of a cycle of treatment. The treatment and rest time make up one “treatment cycle”. When the patient gets to the end of the cycle, it starts again with the next cycle. A series of cycles of treatment is called “a course”.
- As used herein, the term “an immune checkpoint inhibitor (ICI)” refers to a single ICI, a combination of ICIs and a combination of an ICI with another cancer therapy. The ICI may be a monoclonal antibody, a humanized antibody, a fully human antibody, a fusion protein or a combination thereof.
- In one aspect, the invention relates to a method of treating a cancer patient with an immune checkpoint inhibitor (ICI), the method comprising the steps of:
- (i) performing an assay on a blood sample selected from blood plasma, whole blood, blood serum or peripheral blood mononuclear cells obtained from the cancer patient at a time point after a session of treatment with said ICI, to determine the levels of one or more of a plurality of host-driven resistance factors that are driven by the host (“the cancer patient”) in response to treatment with the ICI, said one or more of the plurality of factors promoting in a personalized form responsiveness or non-responsiveness of the cancer patient to the treatment with the ICI;
- (ii) obtaining reference levels for each of the one or more of the plurality of the host-driven resistance factors of step (i) by determining the levels of each of said factors in a blood sample of the same type of the blood sample of step (i), obtained from the cancer patient at a time point before said session of treatment with the ICI;
- (iii) establishing the fold change for each of the one or more of the plurality of the host-driven resistance factors of step (i) by comparing the level of each host-driven resistance factor of step (i) with the reference level of step (ii) for the same factor;
- (iv) determining that the cancer patient has a favorable or a non-favorable response to the treatment with said ICI based on the fold change established in step (iii) for one or more of the plurality of host-driven resistance factors of step (i); and
- (iva) if the cancer patient has a non-favorable response to the treatment with said ICI based on the fold change established in step (iii) for one or more of the plurality of the host-driven resistance factors, then selecting a dominant factor among the one or more host-driven resistance factors showing a fold change indicative of said non-favorable response, and treating the patient with a therapeutically effective amount of the ICI along with a therapeutically effective amount of an agent that blocks the activity of the selected dominant host-driven resistance factor (herein “the dominant factor”), or of the receptor thereof; or
- (ivb) if the cancer patient has a favorable response to the treatment with said ICI based on the fold change established in (iii) for one or more of the plurality of host-driven resistance factors, then continuing the treatment of the cancer patient with the ICI alone.
- A “favorable response” of the cancer patient indicates “responsiveness” of the cancer patient to the treatment with the ICI, namely, the treatment of the responsive cancer patient with the ICI will lead to the desired clinical outcome such as tumor regression, tumor shrinkage or tumor necrosis; an anti-tumor response by the immune system; preventing or delaying tumor recurrence tumor growth or tumor metastasis. In this case, it is possible to continue the treatment of the responsive cancer patient with the ICI alone, as defined in step (ivb) above.
- A “non-favorable response” of the cancer patient indicates “non-responsiveness” of the cancer patient to the treatment with the ICI due to induction of host-driven resistance factors that may be pro-tumorigenic, e.g., pro-angiogenic, pro-inflammatory/chemotactic or proliferative growth factors, or pro-metastatic factors, and thus the treatment of the non-responsive cancer patient with the ICI will not lead to the desired clinical outcome but to non-desired outcomes such as tumor expansion, recurrence and metastases. In order to achieve the desired clinical outcome, it is necessary to blockade the dominant factor as defined above in step (iva) and treating the non-responsive cancer patient with a combination of the ICI and a therapeutic agent that blocks the activity of the selected dominant factor.
- Thus, in one embodiment, the invention relates to a method for treatment of a cancer patient non-responsive to treatment with an immune checkpoint inhibitor (ICI), the method comprising administering to the cancer patient a therapeutically effective amount of the ICI along with a therapeutically effective amount of an agent that blocks the activity of a dominant factor, or of the receptor thereof, the dominant factor being selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, the plurality of host-driven resistance factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the ICI, wherein the fold change is established by comparing: (i) the level of each host-driven resistance factors in a blood sample selected from blood plasma, whole blood, blood serum or peripheral blood mononuclear cells, obtained from the cancer patient after a session of treatment with the ICI, with (ii) a reference level obtained for the same factor from a blood sample of the same type of (i), obtained from the cancer patient before said session of treatment with the ICI.
- In a preferred embodiment, the blood samples of steps (i) and (ii) are both blood plasma. In certain embodiments of the invention, the session of treatment with the ICI is one of multiple sessions of treatment. In certain embodiments, the one of multiple sessions of treatment with the ICI is the first session of treatment with said ICI, the blood sample of step (i) is obtained from the cancer patient at about 20, 24, 30, 36, 40, 48, 50, 60, 72 hours or more, including up to one week or more, up to two weeks or more or up to three weeks or more, after said first session of treatment, and the reference blood sample of step (ii) is obtained from the cancer patient at a time point including at about 72 hours or less, including at about 60, 50, 48, 40, 36, 30, 24 or 20 hours or less or just before said first session of treatment with the ICI.
- In certain embodiments, the one of multiple sessions of treatment of the cancer patient with the ICI is the first session of treatment, when the treatment with the ICI is started. In this case, the reference/baseline sample of step (ii), preferably blood plasma, is obtained from the cancer patient at a time point before starting the treatment including at about 72 hours or less, including at about 60, 50, 48, 40, 36, 30, 24 or 20 hours or just before said first session of treatment with the ICI. The comparison is then made between the concentration levels of the factors determined in the blood sample, preferably blood plasma, obtained from the cancer patient at about 20, 24, 30, 36, 40, 48, 50, 60, 72 hours or more, including up to one week or more, up to two weeks or more, or up to three weeks or more, after said first session of treatment with the ICI.
- In certain other embodiments of the invention, the session of treatment of the cancer patient with the ICI is one of multiple sessions of treatment that is not the first session of treatment with the ICI. In this case, the blood sample is obtained from the cancer patient at any time point between two consecutive sessions of treatment with the ICI and serves simultaneously as the blood sample of step (i) and the reference blood sample according to step (ii) for the next session assay according to step (i). The time between two consecutive sessions of treatment depends on the treatment protocol approved for the specific ICI and may be, for example, of 2 or 3 weeks, depending on the ICI, and the blood sample may be obtained at
day - In accordance with the invention, the levels of the plurality of factors generated by the host/cancer patient in response to the treatment with the immune checkpoint inhibitor are determined in the blood sample, preferably blood plasma, obtained from the patient after treatment with ICI. The value (factor concentration in pg/mL) obtained for each factor is then compared with a reference level, which is the baseline level of concentration of the same factor determined in a blood sample, preferably blood plasma, obtained previously from the same cancer patient (hereinafter “reference/baseline sample”). The change in the level of one or more of the factors identified in the blood sample obtained from the cancer patient after the treatment with the ICI compared to the reference/baseline level, is defined by the fold change for each factor. The fold change for each factor is determined by calculating the ratio of treatment: reference/baseline values for the factor.
- The fold-change of each of the one or more of the plurality of the host-driven resistance factors is considered significant and predictive of a non-favorable response of the cancer patient to the treatment with the ICI if its value is about 1.5 or higher denoting an up-regulation of the factor, or the fold-change is considered significant and predictive of a favorable response of the cancer patient to the treatment with said ICI if its value is about 0.5 or lower denoting down-regulation of the factor.
- In accordance with the invention, the prediction of a favorable or a non-favorable response of the cancer patient to the treatment with an ICI is based on significant fold changes of one or more, optionally two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, fifteen or more, twenty or more, or twenty-five or more, of the host-driven resistance factors.
- The factors/biomarkers induced into the circulation of the cancer patient in response to treatment with the ICI include molecular factors such as cytokines, chemokines, growth factors, enzymes and soluble receptors. The factors may be pro-tumorigenic or pro-metastatic factors. The pro-tumorigenic factors may be pro-angiogenic, pro-inflammatory/chemotactic or proliferative growth factors.
- In certain embodiments, the session of treatment is the first session of a plurality of sessions of treatment of the cancer patient, when the treatment is started. In this case, the comparison is between the factors determined in the blood sample, preferably blood plasma, obtained from the cancer patient after first starting treatment with the ICI, and the same factors found in the reference/baseline blood sample, preferably blood plasma, obtained from the cancer patient before starting treatment with the ICI. The results may assist the medical oncologists treating the patient to decide if or how to continue the treatment of the cancer patient.
- In certain embodiments, the method of the invention is performed for monitoring treatment response in a cancer patient being treated with an ICI. In this case, the session of treatment is one of the sessions of several sessions of treatment, but not the first one. The results will assist the medical oncologist in their decisions if or how to continue the treatment.
- In certain embodiments, the fold change determined for pro-tumorigenic factors is predictive of the patient's favorable response to the cancer therapy and the decision may be to continue the treatment with the same ICI as scheduled.
- In certain embodiments, the fold change determined for pro-tumorigenic factors is predictive of the patient's non-favorable response to the ICI. In this case, depending on the specific biological activity of the pro-tumorigenic factors, the decision may be to continue the treatment with the same ICI but with the addition of a drug that blocks the biological activity of the tumorigenic factors, for example, by adding to the treatment an anti-inflammatory drug if the factors are pro-inflammatory or by adding to the treatment an anti-angiogenic drug if the factors are pro-angiogenic.
- Immune checkpoints are regulators of immune activation. They play a key role in maintaining immune homeostasis and preventing autoimmunity. In cancer, immune checkpoint mechanisms are often activated to suppress the nascent anti-tumor immune response. Immune checkpoint molecules are considered as good targets for cancer immunotherapy. Immune checkpoint inhibitors (ICI) that cause blockade of the immune checkpoint molecules are considered good candidates for the development of drugs for cancer immunotherapy with the potential for use in multiple types of cancers and are already in use or are under development.
- Examples of immune checkpoints that are candidates as targets for development of immune checkpoint inhibitor (ICI) drugs include PD-1 (Programmed Death-1) that has two ligands, PD-L1 and PD-L2; CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4); A2AR (Adenosine A2A receptor), also known as ADORA2A; BT-H3, also called CD276; BT-H4, also called VTCN1; BT-H5; BTLA (B and T Lymphocyte Attenuator), also called CD272; IDO (
Indoleamine 2,3-dioxygenase); KIR (Killer-cell Immunoglobulin-like Receptor); LAG-3 (Lymphocyte Activation Gene-3); TDO (Tryptophan 2,3-dioxygenase); TIM-3 (T-cell Immunoglobulin domain and Mucin domain 3); VISTA (V-domain Ig suppressor of T cell activation). - In certain embodiments of the invention, the ICI is a monoclonal antibody (mAb) against PD-1 or PD-L1 that neutralizes/blocks the PD-1 pathway. In certain embodiments, the anti-PD-1 mAb is Pembrolizumab (Keytruda; formerly called lambrolizumab), approved or tested for treatment of advanced or unresectable melanoma, metastatic non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and recurrent squamous cell carcinoma of the head and neck (SCCH). In certain embodiments, the anti-PD-1 mAb is Nivolumab (Opdivo), approved or tested for NSCLC, RCC, melanoma and colorectal cancer (CRC). In certain embodiments, the anti-PD-1 mAb is Pidilizumab (CT0011), approved or tested for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. In certain embodiments, the anti-PD-1 mAb is REGN2810, AMP-224, MEDI0680, or PDR001.
- In certain other embodiments of the invention, the immune checkpoint inhibitor is a mAb against PD-L1. In certain embodiments, the anti-PD-L1 mAb is Atezolizumab (Tecentriq), Avelumab (Bavencio), or Durvalumab (Imfinzi), approved for multiple cancers. Atezolizumab is being tested in combination with one or two other cancer agents such as bevacizumab, gemcitabine, cisplatin, docetaxel, paclitaxel, vinflunine entinostat, daratumumab, MPDL3280A, carboplatin, Nab-paclitaxel, Radium-223 dichloride, obinutuzumab, for multiple cancers.
- In certain other embodiments of the invention, the ICI is a mAb antibody against CTLA-4. In certain embodiments, the anti-CTLA-4 is Ipilimumab (Yervoy), approved or tested for advanced/metastatic melanoma and castrate-resistant prostate cancer. In certain other embodiments, the anti-CTLA-4 mAb is Tremelimumab (formerly ticilimumab).
- In certain embodiments, the ICI is an inhibitor including: (i) anti-B7-H3, such as MGA271; (ii) anti-IDO, such as epacadostat; (iii) anti-KIR, such as Lirilumab; (iv) anti-LAG-3, such as Relatlimab (BMS-986016), LAG 525, REGN3767; (v) anti-TIM-3, such as TSR022 or MBG453; and (vi) anti-VISTA, such as JNJ 61610588.
- In certain embodiments, a combination of two ICIs is used according to the invention. In certain embodiments, the combination comprises an anti-PD-1 and an anti-CTLA-4, e.g., Nivolumab-Ipilimumab and REGN2810-Ipilimumab. In certain embodiments, the combination comprises an anti-PD-L1 and an anti-CTLA-4, e.g., Durvalumab-Tremelimumab. In certain embodiments, the combination comprises an anti-PD-1 and an anti-PD-L1, e.g., Nivolumab-Atezolimumab. In certain embodiments, the combination comprises an anti-LAG-3 and an anti-PD-1, e.g., Relatlimab-Nivolumab or REGN3767-REGN2810. In certain embodiments, the combination comprises an anti-PD-1 and an MO inhibitor, e.g., Pembrolizurriab and Epacadostat and Nivolumab-Epacadostat.
- Costimulatory molecules such as CD137 (4-1BB), CD134 (OX40), glucocorticoid-induced TNFR (GITR; CD357), and CD40 are expressed by activated T cells, activated natural killer (NK) cells, natural killer T (NKT) cells, Tregs, and other immune cells. The inhibition of the immune checkpoint PD-1 and stimulation of costimulatoiy molecules by agonist antibodies are complementary strategies to enhance immune responses and therefore provide a strong rationale for use in combination. Thus, in certain embodiments, the invention encompasses a combination of an ICI with an agonistic mAb against T-cell co-stimulatory molecules including an anti-ICOS mAb, e.g., MEDI-570 or BMS-986226; an anti-OX40 mAb e.g., MOXR0916, KHK4083, MEDI0562 or MEDI6469; an anti-CD40 mAb; and an anti-CD137 (4-IBB) mAb, e.g., Urelumab or Utomilumab.
- In certain embodiments of the invention, the ICI is administered in combination with one or more conventional cancer therapy including chemotherapy, targeted cancer therapy and radiotherapy. Combinations of ICI and radiation therapy have been studied in multiple clinical trials.
- In certain embodiments, the ICI is used in combination chemotherapy that may be with a single or a combination of chemotherapy drugs, or metronomic chemotherapy. The combinations Pembrolizumab+carboplatin+paclitaxel, Pembrolizumab+gemcitabine+docetaxel, Nivolumab+gemcitabine+cisplatin, Ipilimumab+carboplatin+paclitaxel, and other combinations were tested or are being tested in clinical trials.
- In certain embodiments, the ICI therapy is used in combination with targeted cancer therapy, sometimes called “molecularly targeted therapy”. In certain embodiments, the targeted therapy drugs are small molecules such as bortezomib (Velcade), sunitinib (Sutent). In certain embodiments, the targeted therapy drugs are monoclonal antibodies such as bevacizumab (Avastin), panitumumab (Vectibix), daratumumab (Darzalex). In certain embodiments, an anti-PD-1 is used in combination with sunitinib (Sutent) or pazopanib (Votrient) that was tested for treatment of RCC, or a combination of anti-CTLA-4 ipilimumab with BRAF inhibitor dabrafenib (Tafinlar).
- In certain embodiments, the ICI therapy is used in combination with anti-angiogenic therapy, for example, with a mAb that targets VEGF. Thus, the combination may be of Ipilimumab and bevacizumab.
- In certain embodiments, the ICI therapy is used in combination with other immunotherapies such as cancer vaccines, immunomodulators, immunostimulatory cytokines, e.g., GM-CSF, IFN-α, TGF-β, IL-10, IL-2, IL-15, IL-1.8, and IL-21, or oncolytic viruses. In certain embodiments, anti-CTLA-4 ipilimumab or anti-PD-1 pembrolizumab is used in combination with oncolytic virus talimogene laherparepvec (I-VIE).
- In accordance with the invention, the cancer therapy is related to all types of cancer, primary or metastatic, in all stages of the disease, including, but without being limited to, a primary or a metastatic cancer including bladder, bone, breast, brain, cervical, colon, colorectal, esophageal, gastric cancer, gastrointestinal, glioblastoma, head and neck, head and neck squamous cell cancer, hepatocellular cancer, kidney, liver, lung including small cell lung cancer and non-small cell lung cancer (NSCLC), melanoma, nasopharyngeal, ovarian, pancreas, penile, prostate, skin, testicular, thymus, thyroid, urogenital, or uterine cancer, leukemia, lymphoma, multiple myeloma and sarcoma.
- In certain embodiments, the cancer is leukemia, a cancer of the body's blood-forming tissues, including the bone marrow and the lymphatic system. In certain embodiments, the leukemia is selected from acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) or chronic myeloid leukemia (CML). In certain embodiments, the cancer is multiple myeloma.
- In certain embodiments, the cancer is non-small cell lung cancer (NSCLC). In certain embodiments, the cancer is advanced (stage III or IV) or metastatic NSCLC.
- In certain embodiments the cancer is metastatic melanoma, renal-cell carcinoma (RCC), classic Hodgkin's lymphoma (HL), bladder carcinoma, Merkel cell carcinoma, head and neck cancer, or solid tumors with mismatch repair-deficiency
- The host-driven factors/biomarkers identified by the method of the invention after administration of an immune checkpoint inhibitor to a cancer patient are specific to: (i) the cancer patient; and (ii) the immune checkpoint inhibitor. This is the “host response” that provides specific information about the cancer patient and allows the prediction in a personalized form to help diagnose, plan treatment, find out how well treatment is working, or make a prognosis
- If the treatment is with one single ICI, the factors generated by the host/patient are specific to this particular ICI. If the treatment is carried out with a combination of two ICIs, the factors generated by the host/patient are specific to this combination of ICIs. If treatment is with the ICI in combination with another cancer therapy, the factors generated by the host/patient are specific to this combination.
- In certain embodiments, the biomarkers are molecular factors such as cytokines, chemokines, growth factors, enzymes or soluble receptors. Some of these factors induce cells that affect the tumor and contribute to tumor angiogenesis and cancer re-growth, thereby promoting resistance to the therapy used. Examples of such cells include bone-marrow derived cells (BMDCs) that are mobilized from the bone-marrow compartment by cytokines and growth factors such as G-CSF and SDF-1α, and subsequently colonize the treated tumors and promote cancer therapy resistance, particularly, but not exclusively, chemotherapy resistance. Other cells are immune cells such as macrophages and antigen-presenting cells, or stromal cells within the tumor microenvironment which play a pivotal role in tumor progression.
- The host-mediated cellular and molecular mechanisms that contribute to tumor resistance to a cancer therapy are based on the biological functions of the factors and/or cells generated in the host by the particular cancer therapy. Each factor may exhibit one or more biological functions or activities.
- In certain embodiments, the factors are tumorigenic and contribute to tumor growth. In certain embodiments, the tumorigenic factors are pro-angiogenic. In other embodiments, the tumorigenic factors are pro-inflammatory/chemotactic. In yet other embodiments, the tumorigenic factors are proliferative growth factors.
- In certain embodiments, the pro-angiogenic factors include, without being limited to, ANG (angiogenin); angiopoietin-1; angiopoietin-2; bNGF (basic nerve growth factor); cathepsin S; Galectin-7; GCP-2 (granulocyte chemotactic protein, CXCL6); G-CSF (granulocyte-colony stimulating factor); GM-CSF (granulocyte-macrophage colony stimulating factor, also known as colony-stimulating
factor 2, CSF2); PAI-1 (plasminogen activator Inhibitor-1); PDGF (platelet-derived growth factor) selected from PDGF-AA, PDGF-BB, PDGF-AB; P1GF (or PLGF, placental growth factor); P1GF-2; SCF (stem-cell factor); SDF-1(CXCL12, stromal cell-derived factor-1); Tie2 (or TIE-2, an endothelial receptor tyrosine kinase); VEGF (vascular endothelial growth factor) selected from VEGF-A, VEGF-C and VEGF-D; VEGF-R1; VEGF-R2; VEGF-R3. - In certain embodiments, the pro-inflammatory and/or chemotactic factors include, without being limited to, 6Ckine (CCL21, Exodus-2); angiopoietin-1; angiopoietin-2; BLC (CXCL13, B lymphocyte chemoattractant or B cell-attracting chemokine 1 (BCA-1); BRAK (CXCL14); CD186 (CXCR6); ENA-78 (CXCL5, Epithelial cell derived neutrophil activating peptide 78,); Eotaxin-1 (CCL11); Eotaxin-2 (CCL24); Eotaxin-3 (CCL26); EpCAM (Epithelial cell adhesion molecule); GDF-15 (growth differentiation factor 15, also known as macrophage inhibitory cytokine-1, MIC-1); GM-CSF; GRO (growth-regulated oncogene); HCC-4 (CCL16, human CC chemokine 4); I-309 (CCL1); IFN-γ; IL-1α; IL-1β; IL-1R4 (ST2); IL-2; IL-2R; IL-3; IL-3Rα; IL-5; IL-6; IL-6R; IL-7; IL-8; IL-8 RB (CXCR2, interleukin 8 receptor, beta); IL-11; IL-12; IL-12p40; IL-12p70; IL-13; IL-13 R1; IL-13R2; IL-15; IL-15Rα; IL-16; IL-17; IL-17C; IL-17E; IL-17F; IL-17R; IL-18; IL-18BPa; IL-18 Rα; IL-20; IL-23; IL-27; IL-28; IL-31; IL-33; IP-10 (CXCL10, interferon gamma-inducible protein 10); I-TAC (CXCL11, Interferon-inducible T-cell alpha chemoattractant); LIF (Leukemia inhibitory factor); LIX (CXCL5, lypopolysaccharide-induced CXC chemokine); LRP6 (low-density lipoprotein (LDL) receptor-related protein-6); MadCAM-1 (mucosal addressin cell adhesion molecule 1); MCP-1(CCL2, monocyte chemotactic protein 1); MCP-2 (CCL8); MCP-3 (CCL7); MCP-4 (CCL13); M-CSF (macrophage colony-stimulating factor, also known as colony stimulating factor 1 (CSF1); MIF (macrophage migration inhibitory factor); MIG (XCL9, Monokine induced by gamma interferon); MIP-1 gamma (CCL9, macrophage inflammatory protein-1 gamma); MIP-1α (CCL3); MIP-1β; MIP-1δ (CCL15); MIP-3α (CCL20); MIP-3β (CCL19); (CCL23, Myeloid progenitor inhibitory factor 1); PARC (CCL18, pulmonary and activation-regulated chemokine); PF4 (CXCL4, platelet factor 4); RANTES (CCL5, regulated on activation, normal T cell expressed and secreted); Resistin; SCF; SCYB16 (CXCL16, small inducible cytokine B16); TACI (transmembrane activator and CAML interactor); TARC (CCL17, CC thymus and activation related chemokine); TSLP (Thymic stromal lymphopoietin); TNF-α (tumor necrosis factor-a); TNF R1; TRAIL-R4 (TNF-Related Apoptosis-Inducing Ligand Receptor 4); TREM-1 (Triggering Receptor Expressed On Myeloid Cells 1).
- In certain embodiments, the proliferative factors include, without being limited to, Activin A; Amphiregulin; Axl (AXL, a receptor tyrosine kinase); BDNF (Brain-derived neurotrophic factor); BMP4 (bone morphogenetic protein 4); cathepsin S; EGF (epidermal growth factor); FGF-1 (fibroblast growth factor 1); FGF-2 (also known as bFGF, basic FGF); FGF-7; FGF-21; Follistatin (FST); Galectin-7; Gas6 (growth arrest-specific gene 6); GDF-15; HB-EGF (heparin-binding EGF); HGF; IGFBP-1 (Insulin-like growth factor binding protein-1); IGFBP-3; LAP (Latency-associated peptide); NGF R (nerve growth factor receptor); NrCAM (neuronal cell adhesion molecule); NT-3 (neurotrophin-3); NT-4; PAI-1; TGF-α (transforming growth factor-a); TGF-β; and TGF-β3; TRAIL-R4 (TNF-Related Apoptosis-Inducing Ligand Receptor 4).
- In certain embodiments, the pro-metastatic factors include, without being limited to, ADAMTS1 (A disintegrin and metalloproteinase with thrombospondin motifs 1); cathepsin S; FGF-2; Follistatin (FST); Galectin-7; GCP-2; GDF-15; IGFBP-6; LIF; MMP-9 (Matrix metallopeptidase 9, also known as 92 kDa gelatinase or gelatinase B (GELB); pro-MMP9; RANTES (CCL5); SDF-1 (stromal cell-derived factor-1, also known as CXCL12) and its receptor CXCR4.
- The factors may also be anti-tumorigenic factors, e.g., anti-angiogenic, anti-inflammatory and/or anti-proliferative growth factors.
- In certain embodiments, the circulating factors indicating a host response to ICI include, but are not limited to, ADAMTS1, amphiregulin; Axl; CCL5/RANTES; CCL17/TARC; EGF; Eotaxin-2; FGF-21; Gas6; G-CSF; GM-CSF; HGF; IFN-gamma; IL-1Ralpha; IL-2; IL-6; IL-7; IL-10; IL-12p40; IL-13; IL-33; I-TAC; MadCAM-1; MCP-5; TACI; M-CSF; MMP-9; PDGF-BB; pro-MMP9; SCF.
- In accordance with the present invention, many of the factors that were upregulated in response to anti-PD-1 treatment are key players in pro-tumorigenic and pro-metastatic processes such as angiogenesis, inflammation, chemotaxis and proliferation. Upregulated pro-angiogenic factors include: G-CSF; GM-CSF; and PDGF-BB. Up-regulated pro-inflammatory and/or chemotactic factors include: CCL17/TARC; CCL5/RANTES; G-CSF; GM-CSF; IFN-gamma; IL-1Ralpha; IL-2; IL-6; IL-7; IL-10; IL-12p40; IL-13; IL-33; and M-CSF. Upregulated proliferative growth factors include: FGF-21; Gash; and HGF. Upregulated pro-metastatic factors include: MMP-9.
- In accordance with the present invention, many of the factors that were upregulated in response to anti-PD-L1 treatment are key players in pro-tumorigenic and pro-metastatic processes such as inflammation, chemotaxis and proliferation. Upregulated pro-angiogenic factors include: G-CSF; and SCF. Upregulated pro-inflammatory and/or chemotactic factors include: Eotaxin-2; G-CSF; IL-1ra; IL-6; IL-7; IL-33; I-TAC; MadCAM-1; MCP-5; SCF; and TACI. Upregulated proliferative growth factors include: amphiregulin; Axl; EGF; and HGF. Upregulated pro-metastatic factors include: ADAMT S1 and pro-MMP9.
- As used herein, the term “dominant factor” denotes a potent factor that may be upstream of a signaling pathway that affects a biological process that is vital for the living cell and living organism. These biological processes include proliferation, inflammation, metastasis, and others, and are made of several signaling pathways ultimately leading to activation or inhibition of the biological process. A “signaling pathway” is a row of events in which proteins in the same pathway transfer signal to each other. After the first protein in a pathway receives a signal, it activates another protein which activates another protein and so forth, ultimately leading to activation of one or more cell functions.
- A “dominant factor” may also be a key factor that highly interacts with, and highly affects, many other factors/proteins. According to the invention, the dominant factors are selected based on an algorithm which identifies the protein-protein interactions of factors based on the literature. When a factor has more interactions, it serves as a hub and therefore it is a dominant factor. The term “protein-protein interactions” refers to physical interactions or cross-talk between two or more proteins, resulting in activation or inhibition of signal transduction or protein activity. The term “protein hubs” refers to highly connected proteins that play central and essential role in biological processes and thus may confer the host with resistance, limit or counteract the effectiveness of the treatment of the cancer patient with the cancer therapy modality.
- The terms “block”, “neutralize” or “inhibit” are herein used interchangeably and refer to the capability of an agent of preventing the selected dominant factor from exerting its function/biological activity.
- Examples of dominant factors include, without limitation, Amphiregulin, EGF, EGFR, FGF, IFN-γ, IL-1β, IL-2, IL-6, MMP-9, PDGF, TNF-α and VEGF-A.
- To illustrate their qualifications as dominant factors, the properties of some of these factors is provided herein. Interleukin-1β (IL-1β, IL-1b) is a cytokine member of the IL-1 family, produced by different immune cells including macrophages. It is a potent mediator of the inflammatory response and also known to be involved in several biological processes such as cell proliferation and apoptosis, as well as cell differentiation. IL-1b was mostly investigated as a protein that initiates the pro-inflammatory cascade. It physically interacts with enzymes such as CASP1, IL1RA, IL1R1, CMA1, IL1RB, IL1A, IL1R2; genetically interacts with MAPK8IP2, ZNF675 and UBEN2N; and is co-expressed with A2M, CXCL8, IL18, CAASp1, IL1R1 and others. Thus, IL-1b serves as a hub for interactions with a large number of proteins that affect several biological pathways including cell proliferation, apoptosis and differentiation as well as inflammation and angiogenesis.
- Another dominant factor is Interleukin-6 (IL-6), which is a cytokine that acts mainly as a pro-inflammatory factor but also sometimes as an anti-inflammatory factor produced by muscle cells and as a result downregulate a number of pro-inflammatory proteins such as IL-1, IL-10 and TNF-α. IL-6 is involved in a number of biological processes including bone formation, disruption of blood brain barrier, macrophage activation and innate immune system contribution, stimulates the synthesis of neutrophils and B cells, and is also involved in neurological activities such as disorders, stress and depression. IL6 interacts and affects a large number of proteins: it physically interacts with HRH1, OSM, IL6ST, IL6R and ZBTB16, and was found to be co-expressed with a large number of proteins such as PTPRE, CSF3, CCL2, CXCL8, CXCL3, ICAM1 SELE, NFKBIZ among others. IL6 is involved in a number of pathways mediated by proteins such as LRPPRC, OSM, PTPRE, PIAS1 and IL6R. As such, IL6 serves as a dominant factor for a number of biological processes involved in immune cell activity, cell genesis, and cell-cell interactions.
- A further dominant factor, vascular endothelial growth factor A (VEGF-A), is a growth factor that stimulates the formation of new blood vessels. It is involved in both angiogenesis (endothelial cell proliferation) as well as vasculogenesis (bone marrow-derived endothelial cell precursors and their differentiation). VEGF is important for embryonic cell development and neuronal development in the fetus, and is involved in leukocyte proliferation and differentiation, inflammation and several diseases such as age-related macular degeneration and the majority of cancers. VEGF-A physically interacts with a large number of proteins such as NRP1, NRP2, KDR, FLT1, PGF, THBS1, SPARC, GCP1 and VEGFC; it is co-expressed with SEMA3F, SHB, THBS1, FLT1 and VEGFC; it is involved with proteins of various pathways including PGF, CD2AP, IQGAP1, NEDD4; and it affects a number of biological processes such as angiogenesis, tumorigenesis, cell viability, proliferation and differentiation. As such, VEGF-A is considered a dominant factor, and vital factor for various biological processes both in normal physiological conditions as well as in disease states.
- In certain embodiments, the selected dominant factor shows a fold change of ≥1.5 indicative of a non-favorable response of the cancer patient to the treatment with the ICI, and the treatment of the patient with said ICI may proceed in combination with an agent that blocks said dominant factor or the receptor thereof.
- In certain embodiments, the dominant factor is selected from factors including amphiregulin, EGF, EGFR, FGF, IFN-γ, IL-1β, IL-2, IL-6, MMP9, PDGF, TNF-α and VEGF-A.
- In certain embodiments, the dominant factor is MMP9, the ICI is an anti-PD-1 or anti-PD-L1 monoclonal antibody, and the cancer patient is treated with the ICI in combination with a MMP-9 inhibitor including SB-3CT.
- In certain embodiments, the dominant factor is amphiregulin, the ICI is an anti-PD-1 or anti-PD-L1 monoclonal antibody, and the cancer patient is treated with the ICI in combination with an anti-amphiregulin antibody.
- The invention will now be illustrated by the following non-limiting Examples.
- As discussed hereinbefore, recent clinical studies report that patients may sometimes develop resistance to ICIs, or may not respond to ICI therapy (Sharma et al., 2017). We describe herein that the cancer patient, i.e., the host, generates pro-tumorigenic factors in response to ICI therapy, which in turn contribute to tumor re-growth, progression and resistance to therapy. In order to identify the factors that contribute to this mechanism, we perform our in vivo experiments in both non-tumor- and tumor-bearing immunocompetent mice. This approach allows us to distinguish between the therapeutic anti-tumor activity of ICIs and the effect of these drugs on host cells. We focus on ICIs that are extensively used in the clinic, including anti-PD1, anti-PD-L1 and anti-CTL-4 monoclonal antibodies, and use murine tumor models that are known to be responsive or resistant to specific ICIs. For example, CT26 colon and EMT-6 breast carcinoma cell lines respond to anti-CTLA-4 and anti-PD-L1, respectively (Duraiswamy et al., 2013; Swart et a., 2013), whereas MC38 colon and 4T1 breast carcinoma cell lines are resistant or only modestly responsive to some ICIs (including anti-PD-1) (De Henau et al., 2016; Kodumudi et al., 2016), as also tested in our laboratory (not shown).
- The following antibodies were purchased from BioXCell, West Lebanon, N.H., USA: InVivoMAb anti-mouse-CTLA-4 (cat. #BE0131); InVivoMAb anti-mouse-IL-6 (cat. #BE0046); InVivoMAb anti-mouse-PD-1 (cat. #BE0146); InVivoPlus anti-mouse-PD-L1 (cat. #BE0101); and InVivoMAb Isotype control IgG2b antibody (cat. #BE0090). SB-3CT (IUPAC name: 2-(((4-phenoxyphenyl) sulfonyl)methyl)thiirane) was purchased from MedKoo Biosciences Inc (cat. #406563). Anti-amphiregulin (cat. #AF989) was purchased from R&D systems. A 10 mM stock solution of SB-3CT was prepared in 100% DMSO (Sigma). For in-vivo experiment, the stock solution was diluted to a final concentration of 1.25 mg/ml in 10% DMSO in normal saline.
- Murine EMT6 breast carcinoma and CT26 murine colon carcinoma cells were purchased from the American Type Culture Collection (ATCC, USA). The cells were used in culture for no more than 4 months after being thawed from authentic stocks and were regularly tested and found to be mycoplasma-free (EZ-PCR mycoplasma test kit, Biological Industries, Israel). EMT6 Cells were cultured in Dulbecco's modified eagle medium (DMEM) and CT26 cells were cultured in RPMI 1640 medium, both supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, 1% sodium-pyruvate and 1% penicillin-streptomycin (Biological Industries, Israel). Cells were cultured at 37° C. in 5% CO2.
- Naïve 8-10 week old female BALB/c, SCID or NOD-SCID mice (Harlan, Israel) were used in this study. Experiments were performed in accordance with the Animal Ethic Committee at the Technion (Haifa, Israel). The mice were intraperitoneally injected with anti-PD-1 or irrelevant IgG rat-anti-mouse antibodies (BioXCell, West Lebanon, N.H., USA).
- In other experiments, nave 8-10-week old female and male BALB/c or C57bl/6 mice (Harlan, Israel) were intraperitoneally injected with anti-PD-L1 or irrelevant IgG rat-anti-mouse antibodies (BioXCell, West Lebanon, N.H., USA). In all cases, antibodies were administered at a dose of 200 μg/20 gr mouse, every other day over the period of 1 week (3 injections in total).
- To investigate whether inhibiting host-derived IL-6 improves the efficacy of anti-CTLA-4 treatment, EMT6 murine breast carcinoma cells (5×105) were orthotopically implanted into the mammary fat pad of 8-10-week old BALB/c mice. Tumor size was assessed regularly with Vernier calipers using the formula width2×length×0.5. In some experiments, mice were injected through the tail vein with EMT6 cells (25×103) to form experimental lung metastasis. Mouse survival was monitored daily. When tumors reached a size of 140 mm3, mice (n=5) were intraperitoneally (IP) injected with 200 μg anti-CTLA-4, 200 μg anti-IL-6 or a combination of the two antibodies once every three days (a total of 7 injections). Control mice (n=8) were left untreated. Tumors growth was monitored regularly and when tumor size reached 1500 mm3, mice were sacrificed
- To investigate whether inhibiting host-derived MMP-9 improves the efficacy of anti-PD-L1 therapy, 0.5×106EMT6 GFP murine breast carcinoma cells (a highly selective metastatic clone, called EMT6-F2, previously described for other cell line in Munoz et al., 2006) were orthotopically implanted in the mammary fat pad of 8-weeks old female BALB/c mice (n=7). When tumors reached a size of 100 mm3, mice were IP injected with 200 μg anti-PD-L1, 50 μg SB-3CT (a MMP-2/MMP-9 selective inhibitor) (Kruger A., 2005, Bonfil R D., 2006); or a combination of anti-PD-L1 and SB-3CT. Control mice or mice treated with anti-PD-L1 monotherapy were injected with vehicle control (25% DMSO/65% PEG-200/10% PBS). Tumor growth and mouse survival were monitored and at endpoint (when tumors reached a size of 1500 mm3, or maximum at day 27), mice were sacrificed.
- To determine whether inhibiting host-derived amphiregulin improves the efficacy of anti-PD-L1 therapy, 2×106 CT26 cells were subcutaneously implanted in the right flank of 8-10 weeks old BALB/c mice. When tumors reached a size of 50 mm3, mice were IP injected with 200 μg anti-PD-L1, 5 μg anti-AREG (as previously demonstrated in Fujiu K., 2017) or a combination of anti-PD-L1 and anti-AREG, every 3 days. Control mice were left untreated. Tumor growth and mouse survival were monitored.
- (iii) IL-6 Quantification by ELISA:
- Seven weeks old naïve female BALB/c mice (n=4) were intraperitoneally injected every three days for a total of 3 injections with 200 μg anti-PD-L1 or anti-CTLA-4. Control mice (n=4) were left untreated. One day after the last injection, mice were sacrificed, and blood was collected into EDTA-coated tubes by cardiac puncture. Plasma was isolated by centrifugation of the whole blood at 1300 g for 10 min. at room temperature. Supernatants (representing the plasma layer) were collected and the level of IL-6 was determined by ELISA (IL-6 mouse ELISA Kit, 100712 Abcam) according to the manufacturer's instruction.
- Blood from control IgG-, anti-PD-1-, or anti-PD-L1-treated mice was collected into EDTA-coated tubes by cardiac puncture. Subsequently, plasma was isolated by centrifugation of whole blood at 1000 g, 4° C., for 20 min. Plasma was stored in aliquots at −80° C. until further use. Bone marrow derived cells were flushed from the femurs of IgG or anti-PD-1 treated mice. Bone marrow cells (1×106 cells/ml) were cultured in serum-free DMEM for 24 hours to generate conditioned medium (CM).
- Three protein profiling experiments were performed. In the first experiment, plasma samples extracted from IgG- or anti-PD-1 treated female BALB/c mice were pooled per treatment group (n=5 per group). Samples were applied to a membrane-based Proteome Profiler Mouse XL Cytokine Array (R&D Systems; Cat no: ARY028) according to the manufacturer's instruction to screen a total of 111 factors. In the second experiment, plasma samples extracted from IgG- or anti-PD-L1 treated female or male BALB/c or C57bl/6 mice were pooled per group (n=7 per group). Samples were applied to a glass slide-based Quantibody Mouse Cytokine Array (RayBiotech, Cat no: QAM-CAA-4000) according to the manufacturer's instruction to screen a total of 200 factors. In the third experiment, plasma samples extracted from IgG- or anti-PD-1 treated female BALB/c or SCID mice were pooled per group (n=7 per group). Samples were applied to a glass slide-based Quantibody Mouse Cytokine Array (RayBiotech, Cat no: QAM-CAA-4000) according to the manufacturer's instruction to screen a total of 200 factors. For the membrane-based array, pixel densities on developed X-ray films were analyzed using transmission mode densitometer and image analysis software. For the glass slide-based arrays, the fluorescent readout was detected by a laser fluorescent scanner. In all cases, data was normalized and the fold changes for each factor on the arrays were determined by calculating the ratio of treated: control values.
- Data are expressed as mean±standard deviation (SD). The statistical significance of differences was assessed by one-way ANOVA, followed by Tukey ad hoc statistical test using
GraphPad Prism 5 software (La Jolla, Calif.). Student t-test was used in some experiments when comparing only two groups. Differences between all groups were compared with each other. For the IL-6 quantification by ELISA, the statistical significance of differences was assessed by two tailed unpaired T-test. For tumor growth experiments, statistical significance is assessed by multiple T-test. For survival analysis, differences are assessed by Log-rank Mantle-Cox. Differences were considered significant at p values below 0.05. - Previous experiments suggest that anti-PD-1 therapy induces an upregulation of factors in the circulation which ultimately promotes tumor cell aggressiveness. Such effects may occur in response to other types of immune checkpoint inhibitor therapies. To identify host-derived circulating factors whose levels change in response to anti-PD-1 and anti-PD-L1 therapies, we performed 3 protein array-based screens using naïve (non-tumor bearing) mice. The use of naïve mice allows us to identify factors specifically generated by the host in response to therapy, independent of the tumor.
- In the first screen, naïve 8-10 week old female BALB/c mice (n=3) were intraperitoneally injected with anti-PD-1 rat anti-mouse antibody (BioXCell, West Lebanon, N.H., USA) at a dose of 200 μg/20 gr mouse every other day over a period of 1 week (3 injections in total). Control mice (n=3) were similarly injected with a rat-anti-mouse IgG antibody at the same dose. One week after the first injection, mice were sacrificed, and blood was collected into EDTA-coated tubes by cardiac puncture. Plasma was isolated by centrifugation of whole blood at 1300 g for 10 min. at room temperature. Supernatants (representing the plasma samples) were collected and pooled per group. Aliquots were stored at −80° C. until further use. Plasma samples were applied to a membrane-based Proteome Profiler Mouse XL Cytokine Array (R&D Systems; Cat no: ARY028) to screen a total of 111 factors. A full list of cytokines, enzymes and growth factors detected by the array is shown in Table 1. Pixel densities on developed X-ray films were analyzed using transmission mode densitometer and image analysis software. Normalized data was analyzed to identify factors whose circulating levels were changed in response to anti-PD-1 treatment. Specifically, the fold change was determined for each factor by calculating the ratio of treatment: control values. Factors exhibiting a fold change of more than 1.5 or less than 0.5 were defined as being up- or down-regulated, respectively, in response to anti-PD-1 treatment. These factors and their respective fold changes are listed in Table 2. Many of the factors that were upregulated in response to anti-PD-1 treatment are key players in pro-tumorigenic and pro-metastatic processes such as angiogenesis, inflammation, chemotaxis and proliferation. Upregulated pro-angiogenic factors include: G-CSF; GM-CSF; and PDGF-BB. Up-regulated pro-inflammatory and/or chemotactic factors include: CCL17/TARC; CCL5/RANTES; G-CSF; GM-CSF; IFN-gamma; IL-1Ralpha; IL-2; IL-6; IL-7; IL-10; IL-12p40; IL-13; IL-33; and M-CSF. Upregulated proliferative growth factors include: FGF-21; Gash; and HGF. Upregulated pro-metastatic factors include: MMP-9.
- In the second screen, nave 8-10 week old female BALB/c, male BALB/c, female C57Bl/6 or male C57Bl/6 mice (n=7 mice per group) were intra-peritoneally injected with anti-PD-L1 or control IgG antibodies (BioXCell, West Lebanon, N.H., USA) every other day over a period of 1 week (3 injections in total) at a dose of 200m/20 gr mouse per injection. Twenty-four hours after the last administration, mice were sacrificed, blood was drawn and plasma was prepared. Plasma samples from each group were pooled and applied to a glass slide-based Quantibody Mouse Cytokine Array (RayBiotech, Cat no: QAM-CAA-4000) according to the manufacturer's instruction to screen a total of 200 factors. A full list of cytokines, enzymes and growth factors detected by the array is shown in Table 3. The fold changes were determined for each factor on the protein array by calculating the ratio of treated: control values. Factors exhibiting a fold change of more than 1.5 or less than 0.5 were defined as being up- or down-regulated, respectively, in response to anti-PD-L1 treatment. These factors, and their respective fold changes are listed in Table 4. The data demonstrate that the profiles of up- and down-regulated factors do not completely overlap when comparing between the different mouse strains or when comparing between males and females of the same strain. This suggests that the response to anti-PD-L1 treatment is genotype-dependent. This may reflect differences known to exist also among cancer patients, and therefore provides a rationale for testing the response of the host in patients in a personalized manner. Many of the factors that were upregulated in response to anti-PD-L1 treatment are key players in pro-tumorigenic and pro-metastatic processes such as inflammation, chemotaxis and proliferation. Upregulated pro-angiogenic factors include: G-CSF; and SCF. Upregulated pro-inflammatory and/or chemotactic factors include: Eotaxin-2; G-CSF; IL-1ra; IL-6; IL-7; IL-33; I-TAC; MadCAM-1; MCP-5; SCF; and TACI. Upregulated proliferative growth factors include: amphiregulin; Axl; EGF; and HGF. Upregulated pro-metastatic factors include: ADAMTS1 and pro-MMP9.
- To gain insight into which host cell types secrete these pro-tumorigenic factors, we performed a similar screen, comparing between BALB/c and SCID mice treated with anti-PD-1 or control IgG antibodies. SCID mice carry the severe combined immune deficiency (SCID) mutation on the BALB/c background, and therefore lack functional adaptive immune cell types (B cells and T cells). Naïve 8-10 week old female BALB/c or SCID mice (n=7 mice per group) were intraperitoneally injected with anti-PD-1 or control IgG antibodies (BioXCell, West Lebanon, N.H., USA) every other day over a period of 1 week (3 injections in total) at a dose of 200m/20 gr mouse per injection. Twenty-four hours after the last administration, mice were sacrificed, blood was drawn and plasma was prepared. Plasma samples from each group were pooled and applied to a glass slide-based Quantibody Mouse Cytokine Array (RayBiotech, Cat no: QAM-CAA-4000) according to the manufacturer's instruction to screen a total of 200 factors. A full list of cytokines, enzymes and growth factors detected by the array is shown in Table 3. The fold changes were determined for each factor on the protein array by calculating the ratio of treated: control values. Factors exhibiting a fold change of more than 1.5 or less than 0.5 were defined as being up- or down-regulated, respectively, in response to anti-PD-1 treatment. These factors, and their respective fold changes are listed in Table 5. Several factors were found to be up-regulated in response to anti-PD-1 treatment, some of which were specific to BALB/c and not SCID mice, e.g., ADAMTS1; amphiregulin, I-TAC and SCF. These results suggest that these specific factors are secreted by cells of the adaptive immune system in response to anti-PD-1 treatment.
- Collectively, these results demonstrate that anti-PD-1 and anti-PD-L1 treatments induce a response in the host that supports tumor progression, counteracting the desired therapeutic effects of immune checkpoint inhibitor therapy.
- Matrix metallopeptidase 9 (MMP9) is an enzyme that belongs to the zinc-metalloproteinases family involved in the degradation of the extracellular matrix. MMP-9 is involved in a variety of biological processes, among them are pro-tumorigenic and tissue regeneration biological processes, including epithelial to mesenchymal transition, cell proliferation, angiogenesis, bone formation and wound healing. MMP-9 is one of the key factors involved in invasion and metastasis. Due to its involvement in various key dominant biological pathways in cancer, for which drugs have been developed as anti-cancer agents, MMP-9 serves as a dominant factor induced in response to ICI therapy, and whose inhibition may improve therapeutic outcome.
- MMP-9 was found to be induced in BALB/c mice following treatment with anti-PD-1 or anti-PD-L1, which demonstrate that: i) MMP-9 is secreted by bone marrow-derived cells of naïve BALB/c mice in response to anti-PD-1 treatment; ii) the plasma level of MMP9 is increased 5.4 fold in response to anti-PD-1 treatment in naïve BALB/c mice (Table 2); and iii) the plasma level of pro-MMP-9 is increased by 2-3 fold in response to anti-PD-L1 treatment in naïve BALB/c mice (Table 4). To investigate whether inhibiting host-derived MMP9 improves the efficacy of anti-PD-1 or anti-PD-L1 therapy, the MMP2/MMP9 selective inhibitor SB-3CT is used in combination with anti-PD-1 or anti-PD-L1 antibodies. EMT6 murine breast carcinoma cells (5×105) are orthotopically implanted in the mammary fat pad of BALB/c mice, age 8-weeks, (Harlan, Israel). Tumor size is assessed regularly with Vernier calipers using the formula width2×length×0.5. When tumors reach a size of 100 mm3, mice are randomly assigned to the following treatment groups (n=6 mice per group): i) control; ii) anti-PD-1 monotherapy; iii) anti-PD-L1 monotherapy; iv) MMP2/MMP9 selective inhibitor SB-3CT monotherapy; v) anti-PD-1 and SB-3CT combination therapy; and vi) anti-PD-L1 and SB-3CT combination therapy. Anti-PD-1, anti-PD-L1 and IgG control antibodies are administered by intraperitoneal injections at a dose of 200 μg/20 g mouse every 3 days. SB-3CT is administered by intraperitoneal injections at a dose of 1 mg/20 g mouse every 3 days. Control mice are injected with IgG antibody and vehicle (10% DMSO in normal saline). Mice receiving either anti-PD-1 or anti-PD-L1 monotherapies are also injected with vehicle (10% DMSO in normal saline). Mice receiving SB3-CT monotherapy are also injected with IgG control antibodies. Tumor growth and mouse survival are monitored. At endpoint (when tumors reach a size of ˜1500 mm3 or until experiment reached 27 days), mice are sacrificed.
- The results, presented in
FIGS. 1A and 1B (tumor volume over time and atday 27, the final experimental day, respectively), demonstrate that mice treated with a combination of anti-PD-L1 and the MMP-2/MMP-9 inhibitor SB-3CT, exhibited reduced tumor size compared to mice treated with vehicle, anti-PD-L1 or SB-3CT alone. The advantage of the combined treatment over treatment with the anti-PD-L1 alone was demonstrated by better response rate in individual mice (FIG. 1C , black versus grey, respectively), where it is clearly shown that 3 out of the 8 mice treated with the combined treatment demonstrated reduced tumor size at end point (day 27) compared to the other mice. Moreover, not only the combined treatment inhibited tumor growth, but also improved mice survival (FIG. 1D ). Namely, mice treated with the combination therapy exhibited increased survival compared to the control mice, mice treated with anti-PD-L1 or mice treated with SB-3CT. These results suggest that inhibition of MMP-2/MMP-9 together with anti-PD-L1 treatment may improve treatment efficacy. - Amphiregulin is one of the ligands of the epidermal growth factor receptor (EGFR). Studies have demonstrated a functional role of amphiregulin in several aspects of tumorigenesis. Amphiregulin was chosen in light of our findings described in Example 1 above, which demonstrate that the plasma levels of amphiregulin are increased 2-3 fold in response to anti-PD-L1 treatment in naïve BALB/c and C57/bl/6 mice (Table 4), and 3.7 fold in response to anti-PD-1 treatment in BALB/c mice (Table 5).
- Amphiregulin is known to be involved in number of biological processes crucial for tumor development such as proliferation, invasion, angiogenesis, metastasis and resistance to apoptosis, proposing that its expression is indicative of non-responsiveness to cancer treatment. Moreover, Amphiregulin is one of the ligands of an important cancer promoting receptor, Epidermal Growth Factor Receptor (EGFR). As such, it is considered a dominant factor with pro-tumorigenic activities, and its inhibition may improve treatment efficacy.
- To investigate whether inhibiting host-derived amphiregulin (which is upregulated in BALB/c mice in response to either anti-PD-1 or anti-PD-L1 treatment) improves the efficacy of anti-PD-L1 therapy, CT26 colon carcinoma cells were subcutaneously implanted into BALB/c mice. When tumors reached a size of 50 mm3, mice were either treated with anti-PD-L1, anti-AREG or anti-PD-L1 and anti-AREG combination therapy while control mice were left untreated. Tumor growth and mouse survival were monitored.
- As demonstrated in
FIG. 2A , treatment with anti-AREG in combination with anti-PD-L1, exhibited lower tumor growth compared to control mice and anti-AREG-treated mice. While no major difference between the average tumor volume of mice treated with the combined therapy and the anti-PD-L1 was observed, the combined therapy demonstrated a complete response (disappearance of the tumors) in 25% of the treated mice while none of the mice treated with anti-PD-L1 demonstrated this phenomenon (FIG. 2B ; The dashed vertical lines represent the days of treatment administration). The higher efficacy of the combined treatment is directly correlated with mice survival (FIG. 2C ). Accordingly, mice treated with the amphiregulin inhibitor in combination with anti-PD-L1 have indicated better survival rates compared to control mice, mice treated with anti-PD-L1 or mice treated with anti-AREG monotherapy. - IL-6 is another dominant factor that was demonstrated above to be highly induced in response to ICI therapy. As presented, IL-6 was increased by 15.6-fold in response to anti-PD-1 treatment in BALB/c mice (Table 2), 1.7-1.8-fold in response to anti-PD-L1 treatment in nave BALB/c and C57/bl/6 mice (Table 4) and 1.8-fold in response to anti-PD-1 treatment in SCID mice (Table 5).
- The induction of IL-6 expression following ICI treatment was further validated using ELISA. Mice injected with anti-PD-L1, anti-CTLA-4 or untreated (control mice) were analyzed for IL-6 level in the plasma using ELISA (IL-6 mouse ELISA Kit, ab 100712, Abcam). As shown in
FIG. 4 , mice treated with anti-PD-L1 and anti-CTLA-4 exhibited a pronounced induction of IL-6 concentration (13.4 and 6.15 pg/ml, respectively) compared to control mice in which IL-6 was undetectable (p values 0.03 and 0.02, respectively). Since this experiment was performed using nave mice, it demonstrates that IL-6 is produced by host cells in response to immune checkpoint inhibitors therapy, independently of tumor presence. - IL-6 is known to be involved in number of biological processes crucial for tumor development including proliferation, angiogenesis, inflammation, differentiation and resistance to apoptosis. In addition, IL-6 is a pro-inflammatory cytokine that have been described as a prognostic factor in cancer. Since IL-6 is located at the top of the pro-inflammatory cascade and have been demonstrated to correlate with metastasis it is considered as a dominant factor with pro-tumorigenic and pro-metastatic activities.
- For this reason, we tested whether blocking of host-derived IL-6 improves the efficacy of anti-PD-L1 treatment. BALB/c mice were subcutaneously injected with CT26 murine colon carcinoma cells. When tumors reached a size of 50 mm3, mice were IP injected with anti-PD-L1, anti-IL-6, or a combination of the two antibodies and control mice were left untreated. Tumors growth was monitored regularly and when reached a size of 2000 mm3 mice were sacrificed. As demonstrated in
FIG. 5A , mice treated with the combination of anti-PD-L1 and anti-IL-6 exhibited reduced tumor growth compared to control, anti-PD-L1 or anti-IL-6 treated mice (p values of 0.003, 0.192 and 0.009, respectively). The advantage of the combined treatment compared to anti-PD-L1 or anti-IL-6 treatments in inhibiting tumor growth was more emphasized when comparing tumor growth in single mice. As demonstrated inFIG. 5B , four out of six mice (57%) treated with anti-PD-L1 in combination with anti-IL-6 showed complete response to the treatment and their tumors disappeared, while in the anti-PD-L1 treated group only one mouse out of the six (16.7%) showed complete response and disappearance of the tumor. - As demonstrated in
FIG. 5C , the combined treatment with anti-PD-L1 and anti-IL-6 not only reduced tumor growth but also improved mice survival (undefined median survival) compared to control, anti-PD-L1 or anti-IL-6 treatments (median survival of 31, 39.5 and 31 days, respectively) (p values 0.0026, 0.3552 and 0.0386, respectively), with about 70% survival after 40 days, compared to 50% for the anti-PD-L1 alone group. - To study whether blocking of host-derived IL-6 upregulated in response to anti-CTLA-4 treatment (demonstrated in
FIG. 4 ) improves the efficacy of the treatment, BALB/c mice were orthotopically injected with EMT6 murine breast carcinoma cells into the mammary fat pad. When tumors reached a size of 100 mm3, mice were IP injected with anti-CTLA-4, anti-IL-6 or a combination of anti-CTLA-4 and anti-IL-6 once every three days (a total of 4 injections). Control mice were left untreated. Tumor growth was monitored regularly and when a size of 1500 mm3 was reached, mice were sacrificed. -
FIG. 5A clearly demonstrates enhanced anti-tumor effect of the combined treatment (anti-CTLA-4 and anti-IL-6) compared to the control, anti-CTLA-4 alone or anti-IL-6 treated mice (p values 0.002, 0.137 and <0.001 respectively). Moreover, three out of five mice (60%) treated with the combined treatment of anti-CTLA-4 and anti-IL-6 showed complete response to the treatment and their tumors completely disappeared at aboutday 35, in contrast to one mouse in the anti-CTLA-4 group, showing that the combined treatment not only inhibited tumor growth but also eradicated the tumor. - Blocking host-derived IL-6 in combination with anti-CTLA-4 also improved mice survival. As shown in
FIG. 5B , mice treated with anti-CTLA-4 in combination with anti-IL-6 exhibited enhanced survival rate (undefined median survival) compared to mice treated with anti-CTLA-4, anti-IL-6 or control mice (median survival of 49, 27 and 27 days, respectively), p values 0.076, 0.0008 and 0.0005, respectively.
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/712,816 US12016900B2 (en) | 2017-06-04 | 2019-12-12 | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762514851P | 2017-06-04 | 2017-06-04 | |
US201762564392P | 2017-09-28 | 2017-09-28 | |
US201762594141P | 2017-12-04 | 2017-12-04 | |
PCT/IL2018/050609 WO2018225063A1 (en) | 2017-06-04 | 2018-06-04 | Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor |
US16/219,203 US11977075B2 (en) | 2017-06-04 | 2018-12-13 | Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors, method of treating cancer, and kit therefor |
US16/712,816 US12016900B2 (en) | 2017-06-04 | 2019-12-12 | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/219,203 Continuation-In-Part US11977075B2 (en) | 2017-06-04 | 2018-12-13 | Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors, method of treating cancer, and kit therefor |
Publications (3)
Publication Number | Publication Date |
---|---|
US20200316173A1 US20200316173A1 (en) | 2020-10-08 |
US20220193194A9 true US20220193194A9 (en) | 2022-06-23 |
US12016900B2 US12016900B2 (en) | 2024-06-25 |
Family
ID=82023891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/712,816 Active US12016900B2 (en) | 2017-06-04 | 2019-12-12 | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
Country Status (1)
Country | Link |
---|---|
US (1) | US12016900B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111718415B (en) * | 2020-07-03 | 2021-02-23 | 上海洛启生物医药技术有限公司 | anti-TIGIT nano antibody and application thereof |
CN113777323A (en) * | 2021-09-08 | 2021-12-10 | 中国医学科学院肿瘤医院 | Application of IL-6 in non-small cell lung cancer immunotherapy |
CN115317493B (en) * | 2022-06-22 | 2023-04-28 | 中山大学 | Application of boric acid micromolecule compound in preparation of drugs for enhancing curative effect of immune checkpoint inhibitor and treating leukemia |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
EP1756309A2 (en) | 2004-06-03 | 2007-02-28 | Bayer HealthCare AG | Methods for predicting and monitoring response to cancer therapy |
US20110064744A1 (en) | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
CA2697106A1 (en) | 2007-08-28 | 2009-03-12 | Donald Bergstrom | Expression profiles of biomarker genes in notch mediated cancers |
WO2010001617A1 (en) | 2008-07-04 | 2010-01-07 | Ono Pharmaceutical Co., Ltd. | Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers |
AU2016250478A1 (en) | 2009-11-24 | 2016-11-17 | Alder Biopharmaceuticals, Inc. | Antibodies to IL-6 and use thereof |
WO2012151574A1 (en) | 2011-05-05 | 2012-11-08 | Duke University | Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics |
RU2659173C2 (en) | 2012-01-13 | 2018-06-28 | Дженентек, Инк. | Biological markers for identifying patients for treatment with vegf antagonists |
AU2013240234B2 (en) | 2012-03-30 | 2017-04-27 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
KR20230070054A (en) | 2013-03-15 | 2023-05-19 | 제넨테크, 인크. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
JP6505713B2 (en) | 2013-09-05 | 2019-04-24 | デンドレオン ファーマシューティカルズ インコーポレイテッド | Humoral immune response to tumor antigens after treatment with cancer antigen-specific active immunotherapy and its relevance to improved clinical outcome |
US20160024585A1 (en) | 2014-05-02 | 2016-01-28 | Duke University | Methods of predicting responsiveness of a cancer to an agent and methods of determining a prognosis for a cancer patient |
US20180079814A1 (en) | 2015-04-01 | 2018-03-22 | Medimmune Limited | Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer |
WO2017011907A1 (en) | 2015-07-17 | 2017-01-26 | Pacylex Pharmaceuticals Inc. | Epigenetic silencing of nmt2 |
CA2995586A1 (en) | 2015-08-06 | 2017-02-09 | The Wistar Institute Of Anatomy And Biology | Combination therapies targeting mitochondrial biogenesis for cancer therapy |
US20180231554A1 (en) | 2015-09-04 | 2018-08-16 | The Brigham And Women's Hospital, Inc. | Programmed cell death (pd-1) inhibitor therapy for patients with pd-1-expressing cancers |
WO2017091072A1 (en) | 2015-11-27 | 2017-06-01 | Birrbeheer B.V. | Butyrate salts for use in inflammatory diseases |
MX2018009247A (en) | 2016-01-28 | 2019-03-11 | Univ Indiana Res & Tech Corp | Use of histone deacetylase inhibitors for enhancing immunotherapies. |
US20190331682A1 (en) | 2016-02-18 | 2019-10-31 | Institut Gustave Roussy | Methods and kits for predicting the sensitivity of a subject to immunotherapy |
AU2017343779A1 (en) | 2016-10-13 | 2019-04-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for predicting response and resistance to CTLA4 blockade in melanoma using a gene expression signature |
UA126386C2 (en) | 2016-12-09 | 2022-09-28 | Осе Іммьюнотерапьютікс | Antibodies and polypeptides directed against cd127 |
AU2018277559A1 (en) | 2017-05-30 | 2019-10-17 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent |
CA3066054A1 (en) | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer therapy and kit therefor |
EP3810280A1 (en) | 2018-05-29 | 2021-04-28 | Oncohost Ltd | Cancer treatment by blocking host-induced il-1 in combination with radiotherapy |
-
2019
- 2019-12-12 US US16/712,816 patent/US12016900B2/en active Active
Non-Patent Citations (5)
Title |
---|
Lavi et al (Journal of Controlled Release, 2007, 123: 123-130) * |
McMichael et al (Clin Canc Res, 2017, 23(2): 489-502) * |
Peng et al (Cancer Research, 2012, 72(20): 5209-5218) * |
Ragnhammar et al (Medical Oncology, 1996, 13: 161-166) * |
Yamazaki et al (Cancer Sci, 2017, 108(5): 1022-1031) * |
Also Published As
Publication number | Publication date |
---|---|
US20200316173A1 (en) | 2020-10-08 |
US12016900B2 (en) | 2024-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019396761A1 (en) | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent | |
US20230030983A1 (en) | Fgfr/pd-1 combination therapy for the treatment of cancer | |
US12016900B2 (en) | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent | |
KR102349677B1 (en) | How to Condition a Patient for T Cell Therapy | |
KR20180011251A (en) | Diagnostic methods for T cell therapy | |
Domanska et al. | The chemokine network, a newly discovered target in high grade gliomas | |
US20160000936A1 (en) | Biomarkers for inflammatory disease and methods of using same | |
US20230088070A1 (en) | Use of il-1beta binding antibodies | |
Bhatia et al. | Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment | |
Sharma et al. | Chemokines network in bone metastasis: Vital regulators of seeding and soiling | |
US20200190183A1 (en) | Method of Treating Cancer with a Cancer Therapy in Combination with Another Therapeutic Agent | |
US20240053326A1 (en) | Testing colon cancer drugs for immunomodulatory effects | |
Heath et al. | Race-related Differences in Sipuleucel-T Response Among Men with Metastatic Castrate-Resistant Prostate Cancer | |
Omokehinde | GP130 Regulation of Breast Cancer Signaling and Bone Dissemination | |
Wilmott et al. | Macrophage-derived CXCL9 and CXCL10 are critically required for anti-tumor immune responses following immune checkpoint blockade 2 | |
Abajo | Angiogenic molecular signature in colorectal cancer: Pharmacogenomic implications for the use of antiangiogenic therapies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: SPECIAL NEW |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
AS | Assignment |
Owner name: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES, ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHAKED, YUVAL;REEL/FRAME:058550/0018 Effective date: 20181220 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
ZAAB | Notice of allowance mailed |
Free format text: ORIGINAL CODE: MN/=. |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |